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ABSTRACT 
 
Platelet-surface interactions are a key mediator in a host’s response to vascular 
biomaterials. Directly after implantation, a wide variety of serum proteins are adsorbed 
onto the surface of vascular devices, many of which activate platelets. Serving as the first 
step in the coagulation cascade, the local activation of platelets sets off a chain of events 
that can ultimately determine the fate of implanted vascular devices. Many material 
engineering approaches have been taken in an effort to reduce this activation; however, the 
most successful method to date remains the systemic delivery of antiplatelet and 
anticoagulant agents. The prevalence of antiplatelet pharmaceutics, coupled with a 
variation in efficacy across a diverse population, has led to an industry focused on the 
personalized assessment of platelet function. 
In this dissertation, methods were developed to address a deficiency in the current 
approach to platelet function testing. No current assays take into account the transient 
interactions of platelets with agonist surfaces, interactions that have the capability to prime 
a platelet population for enhanced adhesion and activation downstream of a stimulus. This 
phenomenon was leveraged here to create a flow cell in which the upstream priming of a 
platelet population by a surface-bound agonist could be assessed by downstream capture 
assay. It was demonstrated that this device is capable of determining the response of a 
platelet population to a variable priming stimulus, both alone and in the presence of 
common antiplatelet agents. To further investigate the priming response of platelets, it was 
 iv 
of interest to develop a method by which to pattern multiple proteins on the same surface, 
thus enabling the measurement of the platelet population response to multiple surface 
bound agonists. Taking advantage of advances in microcontact printing and modern light 
microscopy, a new method by which to deposit multiple aligned patterns of agonists on a 
single substrate was developed. This patterning method was then used to investigate the 
ability of multiple agonists to prime platelets in flowing blood and observe the synergistic 
response that platelets exhibit when primed by multiple pathways. 
Taken collectively, these experiments contribute to the field of platelet activation 
by providing a controlled environment in which to study the priming response of platelets 
following transient exposure to surface bound agonists. This assay provides a platform in 
which the platelet response to a variety of surface coatings, biomaterials, and antiplatelet 
agents can be explored, and establishes a foundation for the further investigation of priming 
pathways in platelets.  
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CHAPTER 1 
 
INTRODUCTION 
 
Cardiovascular disease is currently the leading cause of mortality in the world, and 
accounts for nearly one in three deaths.1 In developed nations, this figure increases to over 
40 % of all deaths, resulting in a large societal and economic burden.2 It is estimated that 
the United States spent over $444 billion on cardiovascular disease (CVD) treatment, 
medication, and lost productivity in 2010 alone, accounting for 1 in every 6 dollars spent 
on healthcare.3,4 Considering the growing rates of obesity and type II diabetes in the United 
States – coupled with an increasing life expectancy – the incidence of CVD is expected to 
rise by 10 % over the next 20 years.5  
CVD often cannot be fully managed by diet and pharmaceutics alone, and surgical 
intervention remains a final option for patients. The total number of inpatient 
cardiovascular procedures in the United States exceeded 7.5 million in 2010, often 
involving the implantation of devices such as catheters, stents, vascular grafts, and heart 
valves.6 Coupled with the life-saving efficacy of these devices are complications arising 
from blood-material interactions.7,8 In fact, patients receiving implanted vascular devices 
are at significantly higher risk of thrombotic events irrespective of device success or 
failure.9 Platelets in particular interact with proteins adhered to implanted surfaces and 
greatly increase the risk of device occlusion or embolism.10,11 As such, it has become 
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compulsory for patients receiving blood contacting devices to be placed on anticoagulant 
and/or antiplatelet medications in order to mitigate risks.12 These medications come with a 
considerable reduction in quality of life, and their administration often must be sustained 
for the life of the patient.13–15 There also exists a significant proportion of the population 
that can be categorized as low- or nonresponders to commonly administered antiplatelet 
therapies, necessitating the clinical use of platelet activity tests to tailor therapeutic 
approaches.16–18 
This introduction presents an overview of the biology of platelets, their interaction 
with proteins present on thrombogenic surfaces, and their subsequent adhesion and 
activation. The concept of platelet priming is introduced, along with potential clinical 
complications related to implanted medical devices. Additionally, common antiplatelet 
therapies are reviewed and the implications of low- or nonresponders are addressed. The 
current methods of testing platelet activity are then discussed and the need for new testing 
methods is presented. Finally, a rationale for this work and an outline of the three main 
studies contained in this dissertation are provided. 
 
1.1 Platelets 
Platelets are small, anucleate cells that perform the primary function of hemostasis 
by initiating the clotting process at sites of vessel injury. Derived from large 
megakaryocytes in the bone marrow, platelets circulate throughout the bloodstream at 
concentrations of between 150,000 and 400,000 cells per µL of blood.19,20 The typical 
lifespan of platelets in circulation is 8 to 9 days, after which they are phagocytosed in the 
spleen or liver.21 
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Circulating platelets are 2-3 µm in diameter and discoid in shape. While they lack 
a nucleus and genomic DNA, they do have a dynamic proteome.19 Genetic information in 
the form of completed mRNA is inherited from precursor megakaryocytes and contained 
in the mitochondria. Protein expression is then carried out by the endoplasmic reticulum 
and ribosomes. Quiescent circulating platelets have low levels of protein translation, 
whereas this process is upregulated in platelets that have been activated through any of a 
variety of signaling pathways. Platelets also contain an active actin cytoskeleton which aids 
in attachment and spreading at sites of injury. 
 
1.1.1 Platelet Function 
The primary function of platelets is to identify sites of vessel injury and initiate the 
clotting cascade. When first encountering a damaged vessel, platelets recognize proteins 
present in the exposed subendothelium and arrest on the vessel surface.22–24 In the case of 
implanted biomaterials, platelets recognize adsorbed blood proteins and attach to the 
surface of the device.25–27 Once stationary, platelets undergo a morphological change from 
their discoid, circulating state to a spread, activated state.28 This morphological change is 
accompanied by the activation of a variety of internal signaling pathways as well as the 
release of the contents of α- and dense granules.29 The contents of these granules include 
growth factors, clotting proteins, activation molecules, and adhesion receptors, all of which 
serve to upregulate the local hemostatic response.30 This response is a crucial part of 
hemostasis in the case of a vessel injury, but poses a significant challenge for the 
biocompatibility of implanted devices. The thrombotic response of platelets can interfere 
with the function of a device (e.g., the occlusion of a small diameter stent) and greatly 
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increases the risk of complications such as embolism and stroke.31,32 As such, the adhesion 
of platelets to surfaces has been a key focus of research into biomaterial 
hemocompatibility. 
 
1.1.2 Platelet Adhesion 
Platelets adhere to surfaces, both natural and artificial, through interactions between 
receptors expressed on platelet membranes and molecules present at the surface of 
interaction. In the case of vessel injury, the two primary proteins of interest are von 
Willebrand factor (vWF) and collagen, while vWF and fibrinogen are the main mediating 
factors for artificial surfaces.33,34 After vessel injury, the extracellular matrix (ECM) of the 
vasculature is exposed to the circulating bloodstream. Collagen, the most abundant protein 
in the ECM and an integral part of the vascular basement membrane, then binds with 
circulating vWF. Short-term interactions with vWF serve to slow down platelets from flow 
and allow more stable bonds with collagen to occur. Similarly, adsorbed vWF serves to 
slow platelets near the surface of biomaterials, which then allows stable bonds to form with 
adsorbed fibrinogen. Figure 1.1 illustrates the main mechanisms of interaction between 
platelets and both vessel lesions and biomaterials.  
 
1.1.2.1 The Adhesive Role of von Willebrand Factor 
Von Willebrand factor is a large (500-20,000 kDa) multimeric protein that 
circulates in the blood plasma at a concentration of 10 µg/mL.19 It is also found in the 
Weibel-Palade bodies of endothelial cells, the α-granules of platelets, and in endothelial 
ECM, all of which can be released or exposed at sites of injury and promote adhesion.35–37 
  
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Diagram of platelet interactions with vessel lesions and biomaterials. Platelets 
first tether to the surface and then roll through short-term interactions between GPIb-IX-V 
and von Willebrand factor. Stronger bonds between GPIIb/IIIa and fibrinogen or collagen 
allow for stable adhesion and spreading. 
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VWF binds to platelets through the glycoprotein receptor complexes GPIb-IX-V and 
GPIIb/IIIa as well as to exposed collagen through the GPIb receptor.38–40  
The primary role of vWF during platelet adhesion is to slow circulating platelets 
enough to allow them to form more stable bonds in a process known as "platelet tethering." 
Soluble vWF does not interact strongly with the platelet GPIb-IX-V receptor complex, but 
once adsorbed to a surface, exposed to high shear, or bound to collagen, vWF undergoes a 
conformational change that exposes its A1 domain, enabling platelet binding.41,42 
Interestingly, vWF has also been shown to mediate platelet-surface interactions at low 
shear rates.43 Immobilized vWF and the platelet expressed GPIb-IX-V complex have 
unusual short-term interactions known as catch bonds.44–46 These bonds are shear 
strengthening, that is, the bond duration increases as increasing tensile force is applied, 
allowing platelets to be captured by surfaces from high-shear flow conditions. 34,47–49 Once 
platelets are slowed down, the diminished bond strength and its high on/off rate, coupled 
with the torque applied by flowing blood, cause platelets to roll or translocate along the 
surface. This rolling interaction keeps platelets in the vicinity of the surface and permits 
stronger bonds to form between platelets and collagen or fibrinogen.  
Binding to the GPIb-IX-V complex also serves as an outside-in method of signal 
transduction, which ultimately results in the activation of platelet GPIIb/IIIa receptors.50,51 
These lead to the arrest and stable adhesion of platelets on procoagulant surfaces through 
the binding of activated GPIIb/IIIa receptors to the RGD (Arginine-Glycine-Aspartate) 
sequence in the C1 domain of vWF as well as the RGD sequences in fibrinogen and 
collagen.52 
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1.1.2.2 The Adhesive Role of Collagen 
Collagen is the most abundant protein in the vascular ECM. Platelets can adhere to 
monomeric collagen, but the fibrillar variants, particularly types I, III, and IV (which give 
structural support to resident endothelial cells), play a pivotal role in the adhesion of 
platelets. Platelets have four receptors associated with collagen: GPVI and integrin α2β1, 
which bind directly to collagen, and GPIIb/IIIa and the GPIb complex, which bind to vWF 
associated with collagen as described above.53–55 
Under static conditions, collagen is able to capture and activate platelets without 
the assistance of cofactors; however, under the conditions of flow that exist in circulation, 
vWF plays an essential role in supporting platelet adhesion and activation.56 VWF and 
collagen have been shown to have a high affinity for one another in their native states.57,58 
This interaction is mediated by the A3 domain of vWF and a 9 residue binding sequence 
within collagen.59–61 This close association between vWF and collagen allows for the 
tethering of platelets to vWF while stronger long-term bonds are formed with collagen.62 
GPVI is a platelet glycoprotein in the immunoglobulin superfamily that binds 
directly to collagen through the repeated Gly-Pro-Hyp (GPO) sequence.63 This low-affinity 
binding causes the clustering of GPVI receptors and initiates a tyrosine phosphorylation 
signaling cascade resulting in the activation of integrin α2β1, as well as initiating platelet 
activation.64 Integrin α2β1 is a type I transmembrane glycoprotein that typically exists in 
an inactivated state on the platelet membrane. Once activated by the binding of collagen to 
GPVI, α2β1 transitions from a low-affinity conformation to a high conformation and binds 
to the Gly-Phe-Hyp-Gly-Glu-Arg (GFOGER) sequence on collagen through its α2-I 
domain.65 These two receptors work collectively in a two-site two-step model to support 
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the stable adhesion of platelets to exposed subendothelium and initiate further signaling 
cascades leading to activation.66 
 
1.1.2.3 The Adhesive Role of Fibrinogen 
Fibrinogen, primarily known for its role in hemostasis as the precursor to fibrin, 
can also mediate platelet adhesion to implanted surfaces.67 After the introduction of a blood 
contacting device, proteins from blood rapidly adsorb to the surface.68,69 Circulating at a 
concentration of 1.5-3 mg/mL, fibrinogen makes up approximately 7 % of the blood protein 
content and due to charge interactions, has a high surface affinity for implanted 
biomaterials.70,71 In its native state, fibrinogen does not interact with quiescent platelets; 
however, once adhered to a surface, it denatures and RGD sites are exposed, leading to 
platelet recognition and activation.72–74 
As with collagen, the interplay between vWF (also adsorbed from plasma) and 
fibrinogen facilitates stable adhesion.62,75 Once tethered and rolling on the surface, platelets 
bind to fibrinogen through activated GPIIb/IIIa to form stable adhesions.76 
 
1.1.3 Platelet Activation 
Platelet activation can occur from a variety of stimuli, including (1) exposure to 
soluble agonists such as thrombin, adenosine diphosphate (ADP), and platelet activating 
factor; (2) adhesion to exposed ECM in injured vessels; (3) adhesion to blood proteins 
adsorbed to artificial surfaces; and (4) physical forces such as high shear stresses. With the 
exception of shear forces, each of these activation processes is characterized by the binding 
of an agonist to a specific receptor on the platelet membrane, leading to both intra- and 
extracellular signaling. Platelet activation is characterized by a number of internal cellular 
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processes, including the transformation of surface adhesion receptors from resting to active 
states, the adhesion to and spreading on thrombotic surfaces, and the release of the contents 
of α- and dense granules.77,78 
Quiescent platelets have a very low affinity for plasma proteins such as fibrinogen 
or vWF. During platelet activation, however, the GPIIb/IIIa receptor undergoes a 
conformational change from a low-affinity to a high-affinity state. This allows the binding 
of soluble and insoluble factors and aids in the aggregation of platelets at the site of injury. 
Active GPIIb/IIIa also allows stable bonds to form between platelets and vWF, collagen, 
and fibrinogen, causing platelets to spread along the surface.19,79 Spreading is a rapid 
morphological change in which a discoid shaped platelet extends filopodia across a 
thrombogenic surface. Early stage spreading platelets are characterized by numerous 
dendritic extensions, while fully spread platelets take on a more rounded, or 'fried egg' 
shape. Figure 1.2 is a differential interference contrast (DIC) image that shows platelets in 
various stages of spreading on a thrombogenic surface.  
Accompanying this spreading is the release of the contents of platelet granules. 
Degranulation occurs when platelet granules merge with the cell membrane and release 
their contents into the bloodstream, which act to enhance the activation response. Contents 
of α-granules include the surface receptor P-Selectin; platelet agonists such as vWF, 
fibronectin, and fibrinogen; as well as prothrombotic agents like platelet factor 4, factor V, 
and factor XIII, while dense granules contain ADP and calcium, both potent platelet 
agonists.80 Through activation and subsequent aggregation on a thrombogenic surface, 
platelets serve to enhance the clotting response via these chemical signals.
  
1
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Figure 1.2: DIC images of platelets spreading on a fibrinogen-coated glass surface. Platelets initially tether to the surface, then form 
stable adhesions through interactions between GPIIb/IIIa and GPIb-IX-V and surface adhered proteins. Next, they extend numerous 
filipodia which serve to increase surface contacts. Finally, these filipodia coalesce into circular lamellae as the platelet becomes fully 
spread. Scale bar represents 8 µm. 
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1.1.4 Platelet Priming 
A relatively new concept in the field of platelet biology is that of "priming." This 
term describes the change in response of an excitable cell type to an agonist that is affected 
by prior exposure to a mediator. Examples of priming have been previously observed in 
various cell types such as neutrophils and myocytes, but have only recently been observed 
in platelets. Recent studies have shown that interactions with certain molecules do not fully 
activate platelets, but do increase their propensity to become active when exposed to an 
agonist at a later time. Thus, it is said that these molecules "prime" platelets for activation.81 
A wide variety of molecules have been identified that prime platelets, including proteins, 
hormones, cytokines, and chemokines.82 It is also known that the majority of platelets that 
contact an injury site or biomaterial do not adhere and continue to be swept downstream 
with the circulation.75,83 It is therefore likely that transient interactions between platelets 
and agonist-covered surfaces create a primed platelet population, a population that has a 
higher propensity to activate and adhere when exposed to a subsequent downstream 
stimulus. Studies done by Corum et al. lend support to this theory as they demonstrate that 
the introduction of a surface adhered platelet agonist is sufficient to prime platelets for 
enhanced adhesion at a downstream location.84,85  
Additional support can be found though computer simulation of platelet activation 
dynamics using models developed by the Fogelson group.86,87 These models account for 
many mechanical and chemical interactions between platelets, soluble species, and vessel 
walls. Designed for small vessels or flow chambers, these models utilize an immersed 
boundary approach to track hundreds of platelets and their interactions with their 
surroundings. Also accounted for are fluid concentrations of activating species secreted by 
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platelets or activating sites on vessel walls. Figure 1.3 shows the result of a simulation in 
which two platelet activating sites are input into the same model.88 Interestingly, the 
downstream site is seen to have a much greater concentration of unbound activated platelets 
in its vicinity than the upstream one. These results also suggest that the history of transient 
contact of platelets with an upstream activating region can be carried downstream as an 
altered or primed state. 
The phenomenon of platelet priming has significant clinical implications, 
especially dealing with the implantation of vascular devices. In addition to material 
concerns, the two sites of anastomosis in a vascular graft may serve as priming regions for 
platelets. Platelets entering through the proximal end of a device encounter a disrupted 
endothelium due to the suturing of the device to the native vessel and may become primed 
after interacting with exposed agonists. Platelets flowing through the device might then 
demonstrate an elevated activation response, regardless of the thrombogenicity of the 
device surface. The distal end of the device could therefore serve as a nucleus for enhanced 
platelet activation. Indeed, it has been shown that in the case of coronary bypass grafts, 89 
% of early failures were due to narrowing at the distal anastomosis.89 A similar trend was 
also observed in a multicenter prospective study of arteriovenous grafts in which 29 % of 
cases presented with inflow stenosis, while 100 % of cases exhibited stenosis on the distal 
end of the device.90 
Additionally, it has long been known that in the case of vascular grafts implanted 
in vessels with high shear rates (e.g., aorta, femoral arteries), the material chosen is of little 
consequence, while in the case of lower shear rates (e.g., coronary arteries), the implanted 
material is of the utmost importance.91 The currently accepted theory posits that shear 
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Figure 1.3: Spatial distribution of activated platelets from a two-lesion simulation. The color distribution represents the number of active 
but unbound platelets after 600 s of flow (from left to right) past two priming regions. Note the higher concentration of active platelets 
near the downstream priming region and further downstream. (Figure courtesy of Dr. Liederman and Dr. Fogelson88) 
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forces, quantified by a term known as the thrombotic threshold velocity, inhibit the 
formation of thrombi in larger vessels.92 It might also possible that platelets primed as they 
enter these grafts are not resident long enough to become fully activated, while those 
primed as they enter lower shear vessels are given the chance to adhere and activate on the 
surface of the device, leading to occlusion.  
Platelet priming is a recently discovered phenomenon that could have far reaching 
consequences in the fields of medical device design, vascular surgery, and perioperative 
care. It has become clear that the spatial distribution of platelet agonists is an important  
factor in flowing systems and must be taken into account when predicting clinical 
outcomes. 
 
1.2 Antiplatelet Therapies 
Unwanted activation of platelets is a large cause of morbidity and mortality in the 
Western world. As such, a large amount of effort has been put into developing 
pharmaceutic interventions to mitigate platelet activation pathways. Three classes of 
antiplatelet agents are currently approved for clinical use: cyclooxygenase (COX) 
inhibitors, ADP P2Y12 receptor antagonists, and GPIIb/IIIa inhibitors.
93,94 
 
1.2.1 Cyclooxygenase Inhibitors 
This category of antiplatelet agents, of which acetylsalicylic acid (ASA) (Aspirin®, 
Bayer) is the most common, act by inhibiting COX-1 and COX-2, enzymes that are 
responsible for the production of potent platelet agonists.95 COX catalyzes the conversion 
of arachidonic acid to prostaglandin H2, which in turn is converted into several compounds 
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including thromboxane A2 (TXA2). TXA2 activates platelets by binding to a G-protein 
coupled receptor on the surface of platelets and increasing the expression of GPIIb/IIIa on 
the cell membrane. ASA functions by diffusing into the catalytic site for the COX enzymes 
and acetylating a key serine residue, which prevents arachidonic acid from being 
catabolized. 
Low doses of ASA are commonly prescribed either solo or in conjunction with 
another antiplatelet therapeutic as an approach to prevent secondary ischemic events in 
individuals receiving implanted vascular devices.96 In fact, ASA is by and far the most 
prescribed drug for antiplatelet therapy. Part of ASA’s popularity is tied to its mechanism 
of action; by permanently inhibiting the COX enzymes, its effect can only be reversed by 
the production of new platelets. Since the average life span of platelets is 8-10 days, only 
10-12 % of platelets are replenished every 24 hours. This allows for a once a day dosing 
scheme, making for an approachable therapy for patients. 
 
1.2.2 P2Y12 Inhibitors 
This class of antiplatelet agents acts on the platelet receptor for ADP, inhibiting the 
recognition of this potent agonist. Clopidogrel (Plavix®, Bristol-Myers Squibb) is one such 
drug that is widely prescribed and functions by binding irreversibly to the P2Y12 receptor 
on the platelet membrane. This orally administered prodrug requires a two-step hepatic 
conversion to its active metabolite and therefore has a slow onset of therapeutic efficacy. 
As such, it is often recommended that clopidogrel be combined with ASA treatment to 
avoid adverse ischemic outcomes. Clopidogrel alone has been shown to be marginally 
more effective than ASA and is recommended to be prescribed only when there is an 
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allergy to ASA or an aggressive therapeutic strategy is necessary.97 Despite its cost and 
limitations, clopidogrel is currently one of the best-selling antiplatelet agents.98,99 
Cangrelor (Kengreal™, The Medicines Company) is another drug that acts on the 
ADP receptor and has only recently been approved by the FDA. This agent is a reversible 
antagonist of the P2Y12 receptor.
100 As an active drug, it has a quick onset and fills a 
perioperative niche that clopidogrel cannot. Cangrelor is administered intravenously during 
percutaneous coronary interventions (PCI)s and has been shown to significantly reduce 
occurrence of myocardial infarction and stent thrombosis when compared to 
clopidogrel.101,102 
 
1.2.3 GPIIb/IIIa Inhibitors 
As with cangrelor, GPIIb/IIIa inhibitors are administered intravenously and 
therefore are only available in a perioperative setting. These drugs target the active 
conformation of GPIIb/IIIa that allows platelets to bind fibrinogen and von Willebrand 
factor, leading to platelet activation and aggregation. Three examples of GPIIb/IIIa 
inhibitors are abciximab (ReoPro®, Eli Lilly), eptifibatide (Integrilin®, Millennium 
Pharmaceuticals), and tirofiban (Aggrastat®, Medicure).103 Abciximab is a monoclonal 
antibody that targets the GPIIb/IIIa receptor and inhibits its function. Eptifibatide is a cyclic 
heptapeptide and tirofiban is a synthetic nonpeptide, each of which binds reversibly to the 
GPIIb/IIIa receptor. These drugs have been approved for use during PCIs and the treatment 
of some acute coronary symptoms. 
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1.2.4 Inter-Patient Variability in Drug Response 
No pharmaceutic therapy is fully efficacious across a diverse population, and ASA 
and clopidogrel – the two most commonly administered antiplatelet drugs – are no 
exception. There has been recent research into interpatient variability in response to each 
of these treatments.93,104,105 Current figures estimate that therapy with ASA at 
recommended doses may be ineffectual in up to 30 % of patients.18,106 This variation can 
be attributed to compounding inflammatory factors, elevated platelet turnover, and genetic 
variations of the COX receptors.107–109 Similarly, the percentage of low responders to 
clopidogrel is estimated to be between 5 % and 40 % of the population, often attributed to 
genetic, cellular, and clinical variations.17,110–112  
Treatment failure with each of these drugs can have serious adverse outcomes, 
including occlusion of grafts or stents, embolic events, myocardial infarction, and death. 
Since such a significant proportion of patients experience lower than expected efficacy 
with these treatments, this presents a huge clinical challenge. Identification and monitoring 
of an individual patient’s response to a particular antiplatelet therapy is therefore essential 
in a clinical setting. Nonresponders in each case can be identified through the use of a 
variety of platelet function tests and therapy can be adjusted accordingly. 
 
1.3 Platelet Function Tests 
Traditionally, basic platelet function tests such as clotting time and aggregometry 
have been used to diagnose and monitor individuals with bleeding disorders.113,114 As more 
research has come to light on the role that platelets perform in thrombosis, however, new 
applications and diagnostic methods have arisen. Platelet function tests are currently being 
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used to manage individuals who are taking a variety of antiplatelet drugs in both the acute 
perioperative and long-term care settings.115,116 Each of these methods utilizes the current 
understanding of platelet biology to measure the activation of platelets in response to a 
provided stimulus and can be divided into four main categories: aggregation tests, shear-
based adhesion tests, flow cytometry, and microfluidic assays. 
 
1.3.1 Aggregation Tests 
The first platelet function tests were based on the most obvious result of an active 
platelet population: aggregation. Once activated, platelets will stick to one another through 
the now high-affinity conformation of GPIIb/IIIa via intermediary plasma molecules such 
as fibrinogen or von Willebrand factor. The tendency of activated platelets to aggregate is 
used as a metric of platelet activity in assays such as light transmission aggregometry and 
VerifyNow® (Accriva Diagnostics). 
 
1.3.1.1 Light Transmission Aggregometry 
Light transmission aggregometry (LTA) has long been the gold standard of platelet 
function testing. LTA was invented in 1962 by Gustav Born, and was initially used to 
diagnose bleeding disorders.117 Today, it remains one of the most commonly used tools to 
assess platelet activity.118–120 In LTA, a suspension of platelet rich plasma (PRP, isolated 
from whole blood via centrifugation) is loaded into a cuvette between a light source and a 
detector. A platelet agonist is added to the cuvette, and the light transmission through the 
sample is measured over time. As platelets activate and aggregate, the opacity of the 
solution will decrease and the light transmission through the sample will increase. 
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Historically, the recorded value was the percentage of total aggregation (versus a sample 
of platelet poor plasma); however, recently, more sophisticated techniques have led to the 
interpretation of the dynamics of aggregation curves, allowing for more specific 
diagnoses.118 One particular advantage of LTA is the ability to activate platelets with a 
variety of different agonists, allowing for the study of many activation pathways. Common 
agonists used include: ADP, collagen, epinephrine, arachidonic acid, and thrombin.116 
Despite its widespread acceptance and use, LTA has greatly suffered from issues 
such as standardization of procedures and interpretation of results across laboratories.121,122 
The preparation of the sample (including selection of anticoagulant, isolation of PRP, and 
handling by laboratory staff) can greatly affect the results generated.122 As such, there has 
been a recent effort to standardize the procedure through the publication of specific 
guidelines.121,123,124 While LTA can be used to monitor and detect the effects of antiplatelet 
therapies, the requirement of a large sample volume, long preparation and test times, and 
specialized equipment make this test less than ideal for a clinical setting. 
 
1.3.1.2 VerifyNow® 
The VerifyNow® system (formally Ultegra Rapid Platelet Function Assay, Accriva) 
is a self-contained point of care test that utilizes the dynamics of aggregation to measure 
platelet activity. Whole blood from a patient is loaded into a cartridge that contains 
fibrinogen-coated beads and platelet agonists. This cartridge is then loaded between a light 
source and detector. Platelets aggregate onto the fibrinogen-coated beads proportionally to 
the number of GPIIb/IIIa receptors activated by the specific stimulus, and the light 
transmission through the sample is measured as the beads agglutinate.125 A proprietary 
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algorithm is then used to convert the light transmission values into somewhat arbitrary 
“platelet aggregation units.” This method was originally developed to monitor the efficacy 
of GPIIb/IIIa antagonists such as abciximab and eptifibatide as they will reduce platelet 
binding to fibrinogen.126 Since the introduction of the GPIIb/IIIa antagonist test, two more 
cartridges have been developed, one to monitor ASA and one to monitor clopidogrel.  
This system provides the ability to do rapid antiplatelet testing in an operative 
setting, allowing for the prediction and prevention of adverse cardiovascular events.127 The 
system is expensive, however, and certain factors such as hematocrit, plasma fibrinogen 
levels, and sample handling can influence the results.126,128 The system is also somewhat 
limited in scope, as it limits users to the three currently available cartridges and obscures 
the actual aggregation curves. 
 
1.3.2 Shear-Based Adhesion Tests 
Fluid mechanical forces have a significant impact on platelet activation and 
adhesion, particularly in high-shear locations such as stenoses. The use of elevated shear 
rates in platelet function tests such as the platelet function analyzer (PFA-100/200®, 
Siemens) and the IMPACT Cone and Plate(let) Analyzer (Diamed) provides a way to 
activate a platelet population in the absence of additional agonists. 
 
1.3.2.1 PFA-100/200® 
The PFA-100/200® is a shear-activated, cartridge-based platelet assay. It was 
originally designed to replace or automate bleeding time tests by mimicking an injured 
blood vessel.129 In this assay, whole blood is drawn through a membrane with a small (150 
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µm) aperture which is coated with either collagen and ADP or collagen and epinephrine.130 
These agonists, combined with the elevated shear at the aperture, serve to activate platelets 
that eventually occlude the membrane. The reduction in flow rate is measured, and the time 
to occlusion is reported.120 Since this is a whole blood assay and it requires a small sample 
size, it is well suited for clinical applications. It is also well suited for the screening of 
hereditary platelet disorders, particularly von Willebrand disease, due to the incorporation 
of a high-shear activation component.130  
The PFA-100/200® systems automate the test and thus eliminate user error; 
however, care must be taken in sample preparation as results are greatly influenced by a 
patient’s platelet count and hematocrit as well as the anticoagulant used.118,131 The PFA-
100/200® is capable of monitoring antiplatelet therapies; however, recent research has 
suggested that it is not reliable enough to accurately monitor patients.132,133 The main 
drawback to this system, however, is that it is a global measure of platelet activity and is 
not specific to any particular pathway. This makes it useful as a broad indicator of a 
patient’s platelet activity, but does not provide any information on particular disorders or 
activation pathways. 
 
1.3.2.2 IMPACT Cone and Plate(let) Analyzer 
The IMPACT Cone and Plate(let) analyzer is another device which utilizes shear 
as the main pathway by which to activate platelets. In this test, whole blood is loaded into 
a chamber with a stationary polystyrene plate, and an opposing conical surface. The cone 
is rotated to produce a high-shear environment (1800 s-1) within the sample and platelets 
are allowed to aggregate on the now plasma-covered polystyrene surface.134–136 The use of 
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a cone and plate geometry allows for a constant wall shear to be imparted on the whole 
sample which is governed by the geometry of the system and the rotational speed of the 
cone.137 After a prescribed magnitude and duration of shear, excess blood is washed away 
and the platelets are stained and imaged in an automated process. The percentage of the 
well that is covered by platelets and the average size of the aggregates are then measured 
and recorded. This assay is advantageous since it uses adhered blood proteins to assist in 
the arrest of activated platelets, thus making a more accurate mimetic environment of an 
implanted biomaterial. The IMPACT system also uses a small sample volume and is an 
automated process, lending support for its use in clinical and laboratory settings.  
This device is limited by the fact that it currently only uses polystyrene plates (in 
terms of biomaterials testing applications) and that it is only a broad indicator of platelet 
function and therefore cannot determine the nature of any particular platelet disorders. The 
cone and plate geometry is also a poor representative of native vessel geometry, and due 
to the nature of the assay, real-time data are not available. This test has recently been 
modified through the addition of platelet agonists so that it can be used to evaluate 
antiplatelet therapies; however, IMPACT has seen limited results in predicting adverse 
outcomes in the clinic.138–141 
 
1.3.3 Flow Cytometry 
Flow cytometric methods offer a highly advanced and specific way to study platelet 
activation states. In a flow cytometric assay, a cell suspension is passed through a flow cell, 
between a focused laser and a detector. This detector can measure not only the size of the 
cells (useful for sorting platelets from red blood cells in a whole blood sample), but also 
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fluorescence given off by tags attached to the cell surface.142 Antibodies specific to any of 
a number of platelet activation markers can be fluorescently conjugated and used to assess 
a platelet population’s state through the presence of these markers on the surface of cells.143 
Two of the most common platelet activation markers measured are P-selectin expression 
(a sign of α-granule secretion) and the active conformation of GPIIb/IIIa.144–147 By 
multiplexing lasers and detectors in the same flow path, multiple activation markers can be 
studied in parallel in the same sample. This method is quick, easy to use, and high 
throughput (~20,000 cells/s) so it is useful in gathering detailed information about a platelet 
population within a sample.  
The effect of antiplatelet drugs can be monitored through the use of various 
combinations of antibodies, agonists, and antiplatelet agents. For example, GPIIb/IIIa 
antagonists are typically monitored by measuring their receptor occupancy through a 
number of direct and indirect methods (competitive binding, receptor blocking, secondary 
binding, etc.).148–150 P2Y12 receptor inhibitors can also be monitored through a vasodilator-
stimulated phosphoprotein (VASP) assay, since the phosphorylation of VASP is dependent 
on the level of activation of the P2Y12 receptor.
151,152 Finally, ASA therapy can be 
monitored through the additional stimulation of a sample with arachidonic acid and 
comparing with nonstimulated controls.153  
Despite its versatility in measuring platelet activation status, flow cytometry has 
significant drawbacks that hinder its use in the clinic. First, the machinery required to 
perform this analysis is relatively large and expensive. Recent innovations have allowed 
for the introduction of benchtop flow cytometers; however, these systems are still priced 
out of the budgets of many primary and secondary care facilities. Additionally, while 
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performing the assay is relatively straightforward, the sample preparation and 
interpretation of results is a delicate process and requires a trained and knowledgeable staff. 
 
1.3.4 Microfluidic Methods 
Recent advances in the production of microfluidic chambers have led to a 
resurgence of perfusion devices for the investigation of platelet activity. The original use 
of perfusion chambers was described by Baumgartner et al. in the 1970s.154,155 This 
technique consisted of an assay in which blood was perfused through an annulus-shaped 
Plexiglas chamber past excised sections of denuded endothelium which served to activate 
and accumulate platelets. Current microfluidic platelet assays operate on the same basic 
principles as these original perfusion chambers, but can now be rapidly prototyped and 
highly customized with different geometries, materials, and for different applications.156,157 
The use of a flow cell allows for the creation of a mimetic environment in which to study 
platelet activation, where factors such as flow rate, wall shear rate, and surface presentation 
of antigens can be precisely tailored to investigate specific pathways.85,158,159 The 
miniaturization and multiplexing of flow channels also allows for the investigation of many 
separate conditions in parallel while maintaining a small sample volume.  
There are several commercially available microfluidic platelet assays, as well as 
several companies providing preassembled flow channels for investigative use.160,161 Since 
they are easy to develop, many individual research groups have also created proprietary 
devices to suit their specific needs.162–164 Various solution or surface-based agonists can be 
introduced to these chambers to provoke platelet activation, including soluble factors, 
surface-bound protein agonists, stenotic high-shear regions, or live endothelial cells.165,166 
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Detection metrics include platelet adhesion to agonists, time to occlusion, levels of soluble 
activation markers, or platelet activity surface markers (when coupled with flow 
cytometry). There has also been research done into the effects of antiplatelet agents on 
platelet activity under flow conditions.167–169  
Microfluidic techniques offer many advantages over more established methods; 
however, the specificity of many assays and the underdevelopment of many devices has 
led to a lack of adoption in clinical settings.157,170 Due to their ability to recreate elements 
of the native coagulation environment, however, microfluidics offers a promising approach 
to the future of clinical diagnostics. 
 
1.4 Dissertation Overview 
The research described herein details the development of a platform for in vitro 
simulation of platelet activation by an upstream platelet agonist: a flow assay that mimics 
a lesion site with variable surface density of platelet-activating molecules in the upstream 
position, thus mirroring the physiological conditions in patients with lesions on a blood 
vessel wall or an implanted vascular device. 
 
1.4.1 Rationale 
The environment in which platelets become activated in vivo is highly complex and 
dynamic, involving rheological, biomechanical, and soluble-agonist forces.171 It therefore 
stands to reason that the most accurate platelet function test will be one that best recreates 
the natural environment in which platelets become activated. Current platelet functionality 
assays lack the flexibility required to present specific agonists (alone or in combination) to 
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a flowing sample of blood and assess the activation response generated. Although 
aggregometry is capable of providing a large amount of information on platelet 
functionality, it is entirely solution based, static, and does not take into account surface-
presented agonists.31,172 The VerifyNow® system does take into account surface-adsorbed 
fibrinogen; however, it lacks flow and relies on artificially introduced solution-based 
agonists. Both the PFA-100/200® and IMPACT introduce shear forces; however, shear is 
only one of many factors that influence platelet activation, and as such, these assays can 
only measure global platelet activity, not a response to any specific agonist. Flow 
cytometry is a powerful technique with which to evaluate the activation state of platelets, 
but it is not a self-contained assay and its clinical utility is limited by its expense and 
complexity.  
Current assays also fall short in their ability to predict adverse clinical outcomes 
based on patient-specific responsiveness to certain antiplatelet therapeutics.173–175 As the 
mechanisms for resistance to antiplatelet therapies are not yet fully understood, there exists 
a great need for an assay that can accurately determine an individual’s response to a 
particular therapeutic approach.  
Perfusion chamber methods have come much closer to providing systems that 
mimic platelet activation conditions in vivo. With the advent of microfluidics, it has 
become routine to create assays in which many factors can be tuned to fit a particular 
investigative need, including: the presentation of agonists (surface or solution based), the 
flow and wall shear rate of the system, the surface coating of the walls of the chamber, the 
wall compliance of the chamber, and the methods used to detect platelet activation. Lacking 
from current flow assay methods, however, is a way to analyze the dynamics of platelet 
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priming. This critical and long overlooked step in the platelet activation process could have 
sweeping consequences in the fields of medical device design and postoperative treatment 
of patients.  
I hypothesize that in order to create a better and more relevant platelet function 
assay, a system needs to take into account not only the physical environment in which a 
platelet becomes activated, but the spatial-temporal environment as well. Through the 
inclusion of the upstream-priming and downstream-activation dynamic, a more relevant 
antiplatelet monitoring assay can be created. 
 
1.4.2 Dissertation Outline 
This dissertation describes the development of a device that presents one or more 
agonists to a flowing sample of whole blood and measures the platelet activation state 
downstream of that agonist. Chapter 2 presents the development of a fluidic device in 
which an agonist is presented to a flowing sample of blood and the activation state of the 
platelet population is measured with a surface capture assay downstream of that agonist. 
The assay design consists of a miniaturized array of flow chambers and takes advantage of 
a phenomenon known as platelet margination in order to increase sensitivity. The device 
is disposable, requires a small sample volume (< 1 mL of whole blood) per run, and a 
typical perfusion lasts 5 min, thus making it an ideal candidate for a variety of clinical uses. 
This assay is verified by titrating the upstream agonist and seeing a varying response in 
downstream platelet adhesion. The utility of this method is then demonstrated through the 
introduction of several antiplatelet agents, showing a marked and dose-dependent decrease 
in platelet activity after administration.  
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Platelets in vivo encounter a complex milieu of surface presented agonists.  In order 
to recreate a more accurate priming environment, it is necessary to be able to create a flow 
cell in which platelets can be stimulated by more than one agonist pathway. Previously, 
there was no method by which to accurately print more than one aligned pattern of agonist 
over a relevant spatial scale. In this assay, the surface presented agonists are patterned on 
a surface using microcontact printing, so it was of interest to develop a method by which 
to modify this procedure to allow for the stamping of multiple aligned patterns on the same 
surface. Chapter 3 details the development of a microcontact patterning method that 
enables the presentation of multiple patterns of agonists in registry to a flowing sample.  
Chapter 4 describes the incorporation of the multiagonist patterning method with 
the flow cell design in order to present combinations of agonists to flowing whole blood 
samples. Through the use of this assay, a combinatorial effect is observed in which the total 
activation of a platelet population stimulated by multiple agonists is seen to be greater than 
the stimulation of any one agonist alone, suggesting a synergistic relationship between 
platelet activation pathways.  
Finally, Chapter 5 provides a summary, perspective, and future directions for this 
research. 
  
CHAPTER 2 
 
FUNCTIONAL ASSAY OF ANTIPLATELET DRUGS BASED ON 
MARGINATION OF PLATELETS IN FLOWING BLOOD1 
 
2.1 Introduction 
Each year, millions of individuals require surgical intervention to deal with 
cardiovascular diseases, oftentimes requiring the assistance of a vascular device such as a 
stent, shunt, or graft.176 A major failure mode of these devices is the formation of a 
thrombus, leading to an occlusion of the device or an embolic event. This haemostatic 
response of the body to foreign materials often necessitates that patients be placed on 
systemic anticoagulants, many of which result in a considerable loss in quality of life. The 
development of antiplatelet agents is hindered by the fact that no current in vitro platelet 
activation assay fully takes into account the conditions under which platelets interact with 
different agonists in vivo and the downstream consequences of such interactions. Our group 
has recently shown that there is a quantitative relationship between transient contacts of 
platelets with upstream immobilized agonists and downstream platelet adhesion and 
                                                 
 1 Adapted with permission from Eichinger, Colin D., Fogelson, Aaron L., and Hlady, Vladimir. 
"Functional assay of antiplatelet drugs based on margination of platelets in flowing blood." Biointerphases 
11, 029805 (2016). Copyright 2016 American Vacuum Society 
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activation, leading to a new perspective on vascular device failures.84 This finding was 
utilized here to design a novel antiplatelet drug efficacy assay that mimics transient platelet 
encounters with exposed agonists at a blood vessel wall lesion, or with procoagulant 
proteins adsorbed to the surface of an implanted vascular device. 
 
2.1.1 Platelet Activation and Adhesion 
It is commonly accepted that upon encountering a blood vessel injury or 
biomaterial, platelets initiate the process of repair by recognizing exposed subendothelial 
proteins via membrane receptors and tethering to the surface.19,177 Platelets roll along the 
surface of the injured vessel or material due to short-term interactions of glycoprotein Ib 
(GPIb) and von Willebrand factor (vWF), then arrest, activate, and aggregate through the 
interactions of glycoprotein IIb/IIIa (GPIIbIIIa) and fibrinogen or collagen.22,23,67 Upon 
adhering, platelets undergo a morphological change and release the contents of their 
granules, which contain additional activation factors.28 These processes lead to an 
amplification of the activation cascade and the formation of a fibrin clot.50 Most platelets 
that contact a locus of injury, however, do not immediately adhere at the site of initial 
contact.83 Those platelets that have made transient contacts with a procoagulant surface 
stimulus remain “primed” for downstream activation as they continue to circulate. We have 
recently demonstrated that a platelet population allowed to transiently interact with a 
stimulating surface patch has an increased propensity to activate and adhere 
downstream.84,85 This phenomenon is largely due to the margination of platelets in flowing 
blood which was utilized here to create a new type of antiplatelet agent assay that takes 
into account the upstream history of platelet-agonist interactions.  
31 
 
2.1.2 Antiplatelet Agents 
Anticoagulant or antiplatelet therapy is often used during and after the surgical 
introduction of a vascular device or repair of a damaged blood vessel to reduce the risk of 
thrombotic complications.12 A large proportion of patients continue to receive these 
therapies indefinitely due to the increased risk of thrombosis and embolism associated with 
damaged vessel walls or with blood contacting implants. Examples of antiplatelet drugs 
currently prescribed include thromboxane inhibitors (acetylsalicylic acid), GPIIb/IIIa 
inhibitors (abciximab, eptifibatide, and tirofiban), and ADP inhibitors (clopidogrel, 
prasugrel, and cangrelor). Despite the prevalence of antiplatelet and anticoagulation agents, 
the lack of relevant platelet function assays has limited the scope of antiplatelet drugs tests 
in vitro. There is currently no optimal system in which to test the effects of antiplatelet 
therapies on the dynamics of platelet activation and adhesion in circulation, since current 
assays for antiplatelet agents tend to approximate only the local effects of vascular injury 
or procoagulant device surfaces. Practically no current in vitro platelet function assay takes 
into account the upstream priming that can occur in vessel injury conditions. Platelet 
aggregometry, for example, in which a platelet agonist is added to whole blood or plasma 
and aggregate formation is recorded, is considered the “gold standard” for platelet 
functionality assays.120 Although aggregometry is capable of providing a large amount of 
information on platelet functionality, it does not provide a circulatory environment that 
accurately mimics adhesion, activation, and aggregation onto an injured blood vessel wall 
or an implanted device.19,118 Other methods, including analysis of activation markers using 
flow cytometry or aggregation using techniques such as thromboelastography, only detect 
bulk platelet activation and do not directly assess surface-induced adhesion and 
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activation.178  
 
2.1.3 Platelet Function Assays 
Most platelet function assays are unable to model the effects of a specific activating 
region and actual vessel flow conditions and specific injury site conditions are typically 
not presented. One exception is the IMPACT cone and plate analyzer (CPA), which was 
developed to more accurately represent natural haemostasis.136 In the CPA, a polystyrene 
plate is used to monitor platelet adhesion and aggregation in a well-defined shear 
environment. Plasma proteins are allowed to adsorb to the surface of a polystyrene plate 
from whole blood, creating a thrombogenic surface. The type and amount of plasma 
proteins that adsorb to the surface are not controlled, however, so no direct correlations 
between specific plasma proteins and platelet function can be elucidated. Recent years have 
also seen the rise in use of microfluidic flow cells as essential tools for studying platelet 
activation and adhesion.156,179 Gutierrez et al. used extracellular matrix (ECM) coated 
substrates to investigate the influence of elevated shear rates on platelet adhesion with 
respect to the GPIIb/IIIa receptor.165 Similar assays have also been used by Maloney et al. 
to investigate patient-specific responses to antiplatelet therapies.168  
While these studies have come closer to simulating vessel wall lesion conditions by 
presenting physiologically relevant substrates to shear and/or ECM activated platelets, the 
influence of transient contacts between platelets and surface bound agonists has been 
overlooked. To investigate this phenomenon, we have developed a flow-based method to 
test the downstream activation of platelets after specific upstream stimulation of platelets 
by transient contacts with mimetic procoagulant agonists. The surface-immobilized 
procoagulant proteins act as platelet agonists in order to mimic exposed subendothelium in 
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a blood vessel lesion or a procoagulant surface of an implanted vascular device. Varying 
the surface density of an upstream agonist can thus mirror a range of pathological 
conditions in patients with lesions on a blood vessel wall.  
 
2.1.4 Novel Flow Assay 
The central premise of the flow assay described here is that by controlling the 
presentation of an upstream agonist (a so-called “priming” region made of covalently 
tethered procoagulant proteins), the subsequent activation of platelets can be determined 
using a downstream platelet “capture” region. This assay is carried out in a miniaturized 
array of flow chambers through which a small volume of blood is perfused. Figure 2.1 
shows the geometry of the upstream agonist priming and downstream capture regions in 
rectangular flow chambers. Due to the geometry of the flow cell, this assay takes advantage 
of a margination phenomenon observed in flowing blood in which platelets are 
concentrated near the vessel wall. Such margination of platelets towards the chamber walls 
is due to the existence of a red blood cell depletion zone established during flow. Spatial 
fractionation of platelets ensures a higher number of contacts between the marginated 
platelet subpopulation and upstream priming and downstream capture regions. This assay 
requires a small sample volume (< 1 mL of whole blood) per run, and a typical perfusion 
lasts 5 min, thus making it an ideal candidate for a variety of clinical uses. 
  
3
4
 
 
 
 
Figure 2.1: Schematic of a flow assay assembly. Protein agonists are deposited on a glass substrate in the priming and capture regions 
by microcontact printing and covalent attachment of proteins is achieved through the use of a commercial NHS ester chemistry 
(Nexterion-H®, Schott). A relief-molded PDMS flow channel is inverted on the stamped surface to create the final assembled device. 
Flow through the device brings blood past the priming region followed by the capture region before exiting the device. Platelets near 
the substrate surface are therefore able to sequentially interact with two surface-bound agonist regions in a controlled flow environment. 
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2.2 Methods 
2.2.1 Flow Cell Design and Creation 
Flow chambers contained an upstream platelet priming area (10 mm in length) and 
a downstream capture region (also 10 mm in length). Flow channel dimensions were 3 mm 
wide, 0.1 mm deep, and 70 mm long. Such dimensions were selected to match 
physiologically relevant venous (~100 s-1) and arterial (500-1000 s-1) shear rates depending 
on the volumetric flow rate used in perfusion.180–183 Each device consisted of a parallel 
array of four flow channels and was designed to fit on a standard 25 mm x 75 mm 
microscope slide (Figure 2.1). The flow chambers were manufactured through relief 
molding of polydimethylsiloxane (PDMS) (Sylgard 184, Dow Corning) on patterned 
polymeric tape. Patterns for the channels were cut out of tape on a xurographic plotter 
(CE5000-60, Graphtec). These patterns were then transferred to the bottom of a mold and 
PDMS was cast into the mold at a ratio of 15:1 polymer to crosslinker by weight. The flow 
chambers were allowed to cure, then released from the mold and cut to final dimensions 
(25 mm x 75 mm). Fluid vias were bored from the top of the PDMS into the flow channels 
to provide access for the inlet and outlet of blood.  
To create platelet priming and capture regions, patches of fibrinogen were 
deposited at specific upstream and downstream locations in each flow cell using a 
microcontact printing (µCP) process described in detail elsewhere.85,184 Briefly, soft 
lithographic stamps were created out of PDMS corresponding to random patterns of µm-
sized islands of varying surface density coverage. The surface of these stamps was coated 
with a fibrinogen solution (1 mg/mL in PBS, Haematologic Technologies Inc.) and allowed 
to dry, then brought into contact with the substrate. The fibrinogen used was highly purified 
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research grade with a 95% clottable fraction. Purity was verified by the supplier using SDS-
PAGE. Covalent linkages between proteins and the glass-based bottom of the flow assay 
were achieved by using commercially available Nexterion-H® (Schott) slides coated with 
a PEO-based polymer containing reactive N-hydroxysuccinimide esters.185,186 After µCP 
of fibrinogen, the slides were rinsed in DDI water prior to assembly to eliminate any 
nonbound protein.  
The downstream analysis of platelet activation was carried out via a surface capture 
assay.84 A printed protein capture region consisting of a 10 mm long patch of 100 % surface 
density coverage of fibrinogen was covalently immobilized to the surface of the flow cell 
45 mm downstream of the priming region. This region served to capture activated platelets 
from the marginated platelet subpopulation. Figure 2.2 shows a schematic of a flow assay 
during platelet perfusion, highlighting the µm-sized islands of covalently attached agonist 
in the priming region at three different surface densities. Devices were assembled by 
inverting the PDMS fluidic channels onto the stamped Nexterion-H® glass substrate. 
Capillary forces held the PDMS in place strongly enough to prevent leakage for the 
duration of the experiments. Prior to all experiments, a solution of human serum albumin 
(1 mg/mL in PBS, Sigma-Aldrich) was perfused through each flow cell to both coat the 
PDMS walls of the chamber and backfill any nonstamped regions of the Nexterion-H® 
slide as adsorbed albumin has been shown to be platelet-inert.187  
 
2.2.2 Flow Cell Operation 
Whole human blood was drawn from healthy donors into buffered 3.2 % (0.105 M) 
sodium citrate and was treated with Phe-Pro-Arg-chloromethylketone (PPACK,
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Figure 2.2: Schematic of flow assay function. The presence of red blood cells in flow creates a margination effect which drives platelets 
towards the chamber walls. An increased number of platelets near the substrate surface relative to the bulk flow increases chances of 
platelet-surface interactions. Platelets near the substrate transiently roll along the surface and become primed through interactions with 
agonists. A variable density of printed agonists in the priming region provide a range of probabilities that a platelet contacting the surface 
in the priming region will interact with a printed agonist. Shown here are fluorescent images of microcontact printed fibrinogen at three 
different surface coverage densities, 30 %, 50 %, and 70 % (scale bar represents 10 µm). Primed platelets continue to flow downstream 
along a platelet-inert surface. Primed platelets encountering the downstream agonist patch have an increased propensity to form stable 
adhesions compared to nonprimed populations. The number of adhered platelets in the capture region is used as an indication of overall 
priming in the platelet population. The inset image is a representative view of platelets adhered to a fibrinogen capture region (scale bar 
represents 20 µm). 
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Haematologic Technologies) to prevent thrombin-induced coagulation. Any additional 
antiplatelet agent was added at this time as experimental conditions dictated. Blood was 
kept in a water bath at 37° C for the duration of the experiment, and polyethylene 
microfluidic tubing connected the flow cell to the vial of blood. Flow was achieved by 
drawing blood through the device using a syringe-pump (Kent Scientific). A flow rate of 
3.6 mL/h produced a shear rate of 200 s-1, which was used in all experiments. Flow was 
sustained for 5 min, after which the device was rinsed with prewarmed Tyrode’s buffer to 
remove any nonattached cells. Attached cells were fixed in 4 % paraformaldehyde, imaged 
using a differential interference contrast microscope (DIC) (Diaphot 300, Nikon), and 
quantified. Adhered platelets were counted in ten randomly selected fields (300 µm x 400 
µm) within the downstream capture region. 
 
2.3 Results 
2.3.1 Upstream Agonist Titration 
Flow cells were created with varying surface coverage densities of fibrinogen in 
the upstream priming region. Densities of 15 %, 30 %, 50 %, 75 %, 85 %, and 100 % were 
used. Negative controls of 0 % surface coverage were run both before and after the 
experiments to ensure that the platelets in the blood sample did not become more active 
over the course of the experiment. Figure 2.3 shows that the number of platelets adhered 
to the downstream capture region increased as the surface density of the immobilized 
agonist in the upstream priming position is increased. This finding indicates that the 
elevated chances of platelets contacting the upstream agonist led to a greater number of 
platelets primed for adhesion downstream. These results demonstrate that precise control 
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Figure 2.3: Stimulus-dependent response of platelet activation. Platelet adhesion to a 
downstream fibrinogen capture region is seen to increase as the density of upstream surface 
bound fibrinogen increases. (**p < 0.0001, *p < 0.05) 
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over the relative activation state of a platelet population is achievable and detectable using 
this device. 
 
2.3.2 Antiplatelet Agents 
Two classes of antiplatelet agents were examined for their ability to attenuate 
platelet activation in response to the upstream agonist. The cyclooxygenase (COX) 
inhibitor acetylsalicylic acid (ASA) (Aspirin®, Bayer) and the two GPIIb/IIIa inhibitors, 
eptifibatide (Integrilin®, Millennium Pharmaceuticals) and tirofiban (Aggrastat®, 
Medicure) were selected as they are all nonprodrug candidates, and thus could be easily 
added to the blood prior to perfusion. 
 
2.3.2.1 COX Inhibitor 
Flow cells were created with 50 %, 85 %, and 100 % coverage of printed fibrinogen 
in the upstream priming region. Two samples of whole blood were prepared, one untreated, 
and one treated with 30 µg/mL ASA in whole blood (i.e., the target blood concentration 
for antiplatelet therapy in adults). Figure 2.4 shows the platelet activation response to 
varying surface densities of upstream fibrinogen with and without ASA premixed in the 
perfusate. While an increasing surface density of priming fibrinogen still resulted in 
increased platelet adhesion, the relative number of adhered platelets significantly decreased 
in the presence of ASA. These results illustrate the sensitivity of this assay in assessing the 
efficacy of antiplatelet agents in response to varying levels of platelet activation. 
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Figure 2.4: Stimulus-dependent response of platelet activation in the presence of 
acetylsalicylic acid. Acetylsalicylic acid (ASA) is seen to attenuate the platelet activation 
response. Platelet adhesion to the capture region increases as the density of the upstream 
priming region increases; however, this rate of increase is diminished in the presence of 
the recommended therapeutic dose of ASA. (**p < 0.0001, *p < 0.01) 
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2.3.2.2 GPIIbIIIa Inhibitors 
Another set of experiments was used to test a different class of antiplatelet agents, 
GPIIbIIIa inhibitors. Specifically, eptifibatide (a cyclic heptapeptide) and tirofiban (a 
nonpeptide inhibitor) were used. Devices were created with 100 % surface coverage of 
fibrinogen in both the priming and capture regions. Whole blood mixed with each of these 
drugs was used as perfusate. Antiplatelet agents were combined with blood at their 
respective target therapeutic blood concentrations (3 µg/mL, eptifibatide or 0.33 µg/mL, 
tirofiban) and also at 1/10 of these target concentrations. Figure 2.5 shows the results of 
the GPIIbIIIa inhibitors on downstream platelet adhesion. Both eptifibatide and tirofiban 
diminished the number of adhered platelets at their target therapeutic concentration and at 
1/10 of that level. At the recommended blood concentration of each of these drugs, results 
were statistically similar to nonprimed controls (i.e., with no agonist present in the 
upstream region). This result illustrates the ability of the assay to assess antiplatelet 
therapies in a dose-sensitive manner. 
 
2.4 Discussion 
This novel flow assay, which mimics a physiologically relevant blood vessel wall 
injury to test platelet function and antiplatelet drug efficacy, was made possible by utilizing 
a dynamic phenomenon by which transient platelet-agonist contacts prime platelets for 
enhanced activation and adhesion downstream. The flow assay emulates a procoagulant 
surface of a vascular device or vessel wall injury by presenting a covalently bound platelet-
priming agonist to flowing whole blood. A second patch of an immobilized proadhesive 
protein downstream of the agonist is used to capture primed platelets. In the present study, 
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Figure 2.5: Dose-dependent response of platelet activation in the presence of GPIIb/IIIa 
inhibitors. GPIIb/IIIa inhibitors attenuate the platelet activation response. Both eptifibatide 
and tirofiban diminish the number of adhered platelets comparable to negative controls at 
the target therapeutic dose. (***p < 0.0001, **p < 0.001, *p < 0.01) 
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fibrinogen was used as the protein in the capture region as it has been previously 
demonstrated to effectively arrest primed platelets84,85; however, other capture proteins 
(e.g., collagen or vWF) could easily be incorporated. This assay would not have the 
required sensitivity without the phenomenon of platelet margination towards flow chamber 
walls in laminar flow of whole blood. The dimensions of the flow channels were chosen to 
increase the chances of a platelet interacting with the chamber walls multiple times by 
exploiting the margination of platelets and the propensity of platelets once marginated to 
remain near the chamber walls. Numerous in vivo observations and in vitro experiments of 
whole blood flowing in tubes or channels have established the existence of a near-wall 
region with few to no red blood cells.188–191 This red cell depletion zone is characterized by 
an enhanced concentration of platelets compared to their overall bulk concentration in the 
blood. The red cell depleted and platelet enriched zone comprises the layer of fluid within 
2-5 µm of the wall, growing thinner as the hematocrit and shear rate increase. Importantly, 
platelet margination substantially increases (by 50-fold or more) the rate of platelet 
contacts with the chamber wall.155 Computational models of whole blood, which simulate 
the motion of collections of red blood cells and platelets suspended in plasma, show the 
temporal development of the red cell depletion zone and the subsequent margination of 
platelets.192–194 These studies also show that the red blood cells along the edge of the red 
cell depletion zone form an effective barrier which strongly inhibits the movement of 
platelets from the near-wall region back into the core flow.192,193 In the context of our flow 
assay, this implies that most of the platelets that contact the upstream priming region will 
remain within a few microns of the wall during their transit through the chamber to the 
downstream capture region, and so have a significant chance of contact with the capture 
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region. 
Transient contacts between primed platelets and the capture region result in the 
arrest of platelets, and the number of arrested platelets has been shown to correlate to the 
overall activation of the platelet population.195 Other methods such as FACS analysis of 
activation-dependent surface markers or β-thromboglobulin plasma levels are more 
commonly used to assess platelet activation.142,145,146 Since the fraction of the platelet 
population that contacts the priming region is rather small (~ 2%), it would be difficult to 
detect such low numbers of active platelets among the whole platelet population using these 
methods. Thus, the combination of platelet margination in flow and a downstream capture 
region allows for the self-selection of activated platelets, making the current assay more 
sensitive than any of the bulk fluid-based platelet activation assays.  
Initially, the surface coverage density of fibrinogen was varied to demonstrate the 
sensitivity of the assay to increasing levels of platelet priming stimulus. As the percent of 
surface coverage increased from 0 % to 100 %, the chance that any given platelet flowing 
past the priming region would contact a fibrinogen patch also increased. The surface 
coverage density of fibrinogen was seen to have an effect on the activation state of the 
platelet population, as increased adhesion was observed in the downstream capture region 
in a dose-dependent manner (Figure 2.3). A similar experiment was repeated in which the 
upstream surface density of bound fibrinogen was varied in the presence of ASA. The 
results indicate that ASA was able to decrease the activation of the platelet population 
relative to nontreated controls. Interestingly, platelet priming was still observed to be 
dependent on the upstream agonist surface density; however, the number of adhered 
platelets was diminished. ASA inhibits COX, which in turn halts the formation of 
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thromboxane A2 (TXA2). By lowering TXA2 levels, a key stimulus for platelet activation 
was reduced. Other pathways to activation remained open, however, indicated by a 
continued (albeit decreased) presence of an active platelet population. 
The antiplatelet drugs tirofiban and eptifibatide were also tested for their ability to 
attenuate platelet activation by surface-bound agonists. These drugs inhibit the GPIIb/IIIa 
receptor on platelets which is presumably responsible for platelet priming by upstream 
fibrinogen. A dose-dependent response was seen when the concentration of each of these 
drugs was varied. The number of adhered platelets downstream was significantly reduced 
even when the drugs were used at 1/10 of their recommended dose, and at the 
recommended dose, adhesion was reduced to levels of the nonprimed control. These results 
show the ability of this assay to detect the dose-dependent efficacy of antiplatelet agents. 
 
2.5 Conclusion 
In summary, these experiments demonstrate the newfound ability to investigate 
specific platelet priming pathways through the use of an upstream agonist, downstream 
surface capture assay. The ability of antiplatelet agents to attenuate this response was also 
shown, suggesting the utility of this flow assay for the screening of current and future 
antiplatelet therapies. Interpatient variations in drug sensitivity has been a well-
documented challenge surrounding this class of drugs; therefore, the ability to detect the 
minimum effective therapeutic dose on a patient by patient basis would have large impact 
on the personalized prescription of such pharmaceutics. 
 
  
CHAPTER 3 
 
MULTIPROTEIN MICROCONTACT PRINTING WITH 
MICROMETER RESOLUTION2 
 
3.1 Introduction 
Cells in their natural environments maintain contact with each other and with 
extracellular matrix through molecular recognition events. These events regulate cellular 
behavior and cell differentiation. Understanding the relationship between the molecular 
recognition events and their effects is ever more important in tissue engineering and 
regenerative medicine. With the increasing use of biomaterials in medicine, better ways to 
interface such materials with cellular systems are being sought using biomimetic strategies; 
that is, creating an artificial environment similar to the natural environment of cells in a 
given tissue. One such approach is to deposit precise spatial patterns of proteins on a 
material that serve to accomplish a biological goal. Recently, protein patterned surfaces 
have been used to control cell adhesion196–200 and to direct the growth of neurons.201–205 
With the understanding that the cellular interactions with ECM are complex, a method that 
allows for the precise transfer of multiple independent protein patterns on the same surface 
                                                 
 2 Adapted with permission from Eichinger, Colin D., Hsiao, Tony W., and Hlady, Vladimir. 
"Multiprotein microcontact printing with micrometer resolution." Langmuir 28.4 (2012): 2238-2243. 
Copyright 2012 American Chemical Society 
48 
 
becomes necessary. Despite advances toward this goal, no current techniques exist with 
the resolution necessary to pattern surfaces with multiple proteins at the cellular scale over 
a sufficiently large area. 
There exist numerous ways to pattern surfaces with proteins, each with inherent 
advantages and disadvantages. The three main methods used today are dip-pen 
nanolithography (DPN),206–208 inkjet printing,209–211 and microcontact printing 
(µCP).184,212–214 DPN capitalizes on the precision of atomic force microscopy (AFM) to 
deposit nanoscale patterns of proteins of interest. This system can be multiplexed with 
many tips, and can be made to deposit multiple proteins in precise registration.207 Motion 
of the tips is accomplished with piezoelectric actuators, while coordinates are programmed 
into a controlling computer, providing for both accuracy and repeatability. Because of the 
precise optics and computer controllers required, this system is relatively costly. The main 
downfall of the DPN technique and its application to biological systems, however, is the 
small scale over which proteins can be deposited. The x and y range of a typical AFM is 
limited to a few hundred micrometers; therefore, a large coverage of surface patterns is 
difficult to achieve in a reasonable amount of time. Multiplexing tips serves to shorten the 
patterning time; however, it results in a pattern repeated across the surface, not a single 
unique pattern. 
Inkjet printing is a rapid surface patterning technique that lends itself to high 
throughput applications. This method, well established for the printing of inks, has recently 
been applied to the patterning of proteins. In inkjet printing, the desired protein solution is 
loaded into a print cartridge. If multiple proteins are to be used, cartridges are selected that 
allow for the printing of multiple solutions in parallel. High-resolution jet printers are then 
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used to deposit a desired protein pattern onto a surface. While this process is rapid and 
relatively cheap, the nonuniform drying of spotted solutions can lead to inhomogeneous 
coverage of the desired patterned regions.215 Additionally, the resolution of these printers 
is limited by the minimum droplet size they can deposit ~20-30 µm.209 This resolution 
limits the application of inkjet printing for cell-pattern interaction studies. 
µCP is a more flexible patterning technique. Taking advantage of established 
photolithographic methods, master dies are made from etched patterns in photoresist or 
metals. These patterns are transferred to a soft polymeric material through casting and 
curing of the polymer in the die. Once the cured polymer is peeled off of the template, it 
can be used as a stamp with which to pattern surfaces with proteins. Polydimethylsiloxane 
(PDMS) is a typical polymer used to create these stamps and is widely available. By 
varying the monomer/cross-linker ratio, stamps with a range of elastic moduli can be 
created, allowing this technique to be tailored to specific applications. With the exception 
of the exposure and etching of the master template, all other steps in the stamp generation 
process can be carried out on the benchtop. This method is limited in minimum achievable 
stamp feature size ~100 nm214; however, it provides for any desired pattern of proteins to 
be deposited over a large area. 
All current soft lithographic techniques are limited in their ability to pattern 
multiple proteins on the same surface. Many groups have addressed this problem with 
innovations such as multiplexing small arrays,216 inkjet printing with multiple inks,217 and 
microfluidic deposition.184,218 While these methods do allow for the deposition of multiple 
proteins on a surface, none allow for large-scale patterning. In order to achieve large area 
coverage of multiple aligned patterns with small features, stamps need to be used to pattern 
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the same substrate in serial. This method has been used by multiple groups,184,219 but has 
been limited by only a rough degree of alignment, typically achieved by eye. In order to 
generate increasingly complex patterns, a more precise and repeatable method is necessary. 
One proposed application of multiplexed protein patterns can be found in the field 
of neuronal regeneration. In healthy tissues, astrocytes guide the growth of neurons though 
a series of molecular cues. When aligned, they express cellular adhesion and guidance 
molecules in specific spatial orientations so as to guide developing neurons along the same 
axis.220 It is thought that by replicating these complex protein patterns, directed neuronal 
outgrowth can be achieved in vitro, an important first step toward neuronal bridging 
devices. Figure 3.1 shows the essential steps of creating such multiple protein patterns: a 
high-resolution image of astrocyte expressed laminin (green) and chondroitin sulfate 
proteoglycan (red) (A) are used to create µCP templates (B) from which the stamps (C) are 
made to print two proteins (D). In order to replicate these natural patterns, a method is 
required that allows for the transfer of multiple complex protein patterns to the same 
surface in precise registration. 
Presented herein is a report on a platform that allows for multiplexed µCP of 
independent patterns with micrometer spatial registration. The device developed consists 
of an inverted light microscope modified to accept both stamp and substrate. The substrate 
is affixed to an optically clear stage at the focal distance of the microscope’s objective, 
providing for real-time imaging of the stamping process. This, along with the use of 
imaging software, allows the user to overlay a live image of a stamp with a previously 
transferred pattern, thus enabling accurate registration of two or more patterns.
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Figure 3.1: Essential steps of creating multiple protein patterns. (A) A high-resolution 
image of astrocyte expressed laminin (stained green), chondroitin sulfate proteoglycan 
(stained red), and cell nucleus (stained blue) (courtesy of F. Meng, Tresco's lab, University 
of Utah). (B) A smaller region of astrocyte membrane is used to create µCP templates for 
two proteins. (C) These templates are used to prepare two µCP stamps with the same 
repeating patterns. (D) The stamps are used to print two proteins in registration. 
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3.2 Methods 
3.2.1 Stamping Platform 
The multiprotein patterning was carried out using a modified inverted light 
microscope (Diaphot, Nikon) equipped with a charge-coupled device (CCD) camera (Orca, 
Hamamatsu) and designed to house both a soft polymeric stamp and a glass substrate 
(Figure 3.2). The microscope could be run either in bright-field, epi-fluorescence, or 
reflectance interference contrast microscopy (RICM) modes.221,222 The stamps were 
mechanically attached to the microscope stage and could be translated in the x, y, and z 
directions as well as rotated in Θx, Θy, Θz relative to the substrate for alignment and 
leveling. The stamp holder consisted of an optical two-axis tilt mount (KMM1, Thorlabs) 
with a custom rotating glass stage. The holder was attached to the microscope stage via 
vertical sliding rails, providing a rough vertical adjustment and ensuring the stamp holder 
was level with respect to the microscope stage. The stamp was held on the glass stage 
simply using capillary forces, allowing for rapid and easy exchange of stamps and 
eliminating the need for adhesives or clamps. Additionally, the lack of mechanical clamps 
prevented deformation of stamp features prior to stamping and preserved the integrity of 
the pattern. The substrate to be stamped was attached to the outer housing of the 
microscope’s objective lens (Nikon, Fluor 10x, NA 0.5) by a custom engineered stage. This 
stage allowed for the use of glass coverslips or microscope slides as substrates, thus also 
facilitating simple substrate exchanges. The stage was optically clear, and the surface to be 
stamped could be brought into the focal plane of the underlying objective, allowing for 
real-time in situ imaging during the stamping process.
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Figure 3.2: Schematic of the multiprotein µCP device. A light microscope was modified to accept stamps and substrates while providing 
real-time imaging capabilities. 
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3.2.2 PDMS Stamps 
The creation of soft lithographic stamps has been previously described in detail.213 
Briefly, photolithographic techniques were used to transfer template patterns onto 
chromium-coated fused silica surfaces. A chromium etch was used to provide for relief of 
features. PDMS (10:1 ratio of base-to-cross-linker by weight) was then cast over the molds 
and allowed to cure. The PDMS stamps were peeled off of the mold and were cleaned by 
sonication in a 1 % solution of surfactant Alconox® (Alconox, New York) for 15 min. 
Stamps were rinsed in ethanol and allowed to dry under nitrogen gas. The stamps were 
then inked with the desired proteins by depositing 100 µL of protein solution on the feature-
side of the stamp and incubating for 30 min. Nonadhered protein was rinsed off with double 
distilled deionized (DDI) water, and the stamps were dried again under a stream of 
nitrogen. 
 
3.2.3 Two-protein Stamping Protocol 
For illustration, a two-protein stamping protocol is described here; however, it 
should be noted that this technique could be easily used to create higher order protein 
patterns. In a two-stamp protocol, the first stamp was placed on the optical two-axis tilt 
mount and fastened to the stage of the inverted light microscope with its inked side facing 
toward an objective lens. A substrate to be stamped was attached to the custom stage on 
the top of the objective (Nikon, Fluor 10x, NA 0.5) (Figure 3.2) and was brought into the 
focal plane of the objective. The microscope turret was then rotated to retract the substrate 
stage and to advance the second, so-called “leveling” objective (Nikon Fluor 20x, NA 0.75) 
below the mounted stamp. Stamp leveling with respect to the substrate was accomplished 
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by translating and imaging each corner of the stamp and ensuring they were in focus by 
adjusting the tilt mount (Θx, Θy) as necessary. Through the use of an objective lens with a 
shallow depth of field, very precise leveling could be achieved, which was important as 
features on the elastomeric stamp can deform differently under a nonuniformly applied 
load. If one portion of the stamp is incident upon the sample first, it will ultimately 
experience a higher load than the rest of the stamp, which may lead to deformed features 
or stamp collapse. 
The microscope turret was then rotated back to advance the substrate below the 
stamp. The stage was lowered to bring the stamp into contact with the surface for five min, 
depositing the protein on the substrate. Using the CCD camera, real-time images of the 
stamping process were generated. This allowed for recording of the stamping process and, 
in the case of RICM images, provided quantitative information as to the actual area of the 
stamp in contact with the surface. When multiple stamped patterns were desired on the 
same substrate surface, an image of the first stamp was recorded using bright field while 
the stamp was in contact with the substrate. The first stamp was then retracted, and a second 
stamp was loaded. The microscope turret was again rotated to advance the leveling 
objective. The second stamp was leveled in the same manner as the first. The turret was 
rotated back to again bring the substrate into place. Using the “overlay” function in 
ImageJ,223 the recorded image of the first stamp in contact with the surface was layered 
over the live image from the microscope. Since the substrate remained stationary in the 
field of view of the camera, the image of the first stamp was representative of the first 
transferred protein pattern on the substrate. The pattern on the second stamp could therefore 
be prealigned with the pattern transferred from the first stamp prior to second stamp-
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substrate contact. The second stamp was then brought into contact with the surface for 5 
min and retracted, resulting in the transfer of the second protein pattern. In this way, 
surfaces with multiple precisely aligned patterns of proteins were generated. Figure 3.3 
shows a schematic of the two-step protocol highlighting the different steps of this process. 
Feature deformation and collapse are two inherent problems in µCP214 and vary 
based on the physical distribution of pillars used to pattern the substrate. Since the substrate 
stage was mounted to an objective lens, real-time in situ imaging was made possible. This 
provided for both qualitative and quantitative information during the stamping process. 
The use of RICM greatly assisted in calibrating the system for each stamp. Using RICM 
mode, the contact area of the stamp was measured, and the effect of various loading forces 
on stamp feature deformation was determined. Figure 3.4a shows an RICM image of a 
random gradient stamp touching a substrate, with contacting features appearing black. 
Using fluorescently labeled proteins in the stamping process, the resulting patterns on the 
substrate were visualized using epifluorescence microscopy. Figure 3.4b shows an example 
of a transferred AlexaFluor 488-labeled laminin (Invitrogen) from the same gradient stamp. 
Using proteins conjugated with different fluorophores, multiple patterns of proteins on the 
same surface were viewed independently, and alignment of the patterns was verified. 
 
3.2.4 Cell Adhesion Experiments 
Primary P1 CD rat astrocytes were seeded onto patterned coverslips at a sub-
monolayer density of approximately 4000 cells/cm2. The cells were cultured at 37° C and 
5 % CO2 for 48 h in Dulbecco's modified Eagle medium (DMEM)/F12 media (Gibco) 
supplemented with 10 % fetal bovine serum (FBS; Sigma). Astrocyte cultures were fixed 
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Figure 3.3: Schematic of the multiprotein µCP process. A stamp is inked and dried (1–2) 
then loaded and leveled using the leveling objective. The substrate stage is advanced with 
the microscope turret, and the stamp is aligned with the previous pattern (3). The stamp is 
then brought into contact with the surface and the protein pattern is transferred (4–5). This 
process is repeated to deposit multiple patterns of proteins. 
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Figure 3.4: Examples of in situ microscopy available in the multiprotein µCP process. (A) RICM image of a gradient patterned stamp 
in contact with a substrate. (B) Fluorescence microscopy image of a transferred laminin (AlexaFluor 488-labeled) protein pattern from 
a gradient stamp. 
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with 4 % paraformaldehyde for 15 min. Fixed samples were treated with 4',6-diamidino-
2-phenylindole (DAPI; Invitrogen) in a 1:100 dilution in phosphate-buffered saline (PBS) 
for 15 min to stain for cell nuclei. Samples were then rinsed in DDI water, dried, and 
mounted with Fluoromount-G (Southern Biotech) for imaging using a fluorescence 
microscope (Nikon Eclipse E600, Plan 20x, NA 0.75). Cell alignment with respect to 
alternating patterns of laminin (Invitrogen) and aggrecan (Sigma-Aldrich) was calculated 
by taking the angle of the longest chord drawn through the nucleus of each cell relative to 
the patterned lanes using Image Pro Plus (Media Cybernetics). Astrocytes cells present in 
aggregates were excluded to eliminate cell–cell interactions from two-protein pattern 
effects. 
 
3.3 Results 
To determine the positional error introduced by the leveling procedure, the 
reproducibility of the microscope turret was investigated. The turret was rotated between 
the sample stage objective and leveling objective 20 times, and an image of a reticle was 
taken each time. These images were used to calculate the variation in set position inherent 
to the microscope turret. The variation was found to be ±1.96 µm in the x direction and 
±1.23 µm in the y direction. 
The registration capability of the device was demonstrated by aligning two stamps: 
the first stamp was based on a randomized 20 % coverage pattern generated using 
Mathematica’s (Wolfram) random function with the smallest feature size being 1 µm2, 
while the second stamp was its inverse.85 Figure 3.5a represents a subsection of the 
template used to generate the 20 % coverage stamp, and Figure 3.5b shows a bright field 
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Figure 3.5: The registration capability of the multiprotein µCP process. (A) A subsection 
of a random 20 % coverage pattern. (B) Bright field image of a randomized 20 % coverage 
stamp. (C) A subsection of the complementary 80 % coverage pattern. (D) Bright field 
image of a complementary 80 % coverage stamp. (E) Overlay of the two stamps as seen 
by operator during the alignment step. False color was added for contrast. 
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image of the corresponding portion of the stamp. Figures 3.5c and 3.5d shows the same for 
the complementary 80 % coverage stamp. Figure 3.5e shows an overlay of an image of the 
20 % stamp with the live CCD feed of the 80 % stamp during alignment. Colors are added 
to provide contrast between the features of each stamp. 
The precision in printing two different proteins was demonstrated through the use 
of stamps that were patterned with 15 µm lanes spaced 25 μm apart. Figure 3.6 shows the 
printing of AlexaFluor 488-labeled laminin using the first stamp and AlexaFluor 592-
labeled aggrecan using a second stamp with identical features on the same substrate surface 
at various inter-lane spacings. Figure 3.6a shows lanes printed with an intended space of 0 
µm between them, while Figure 3.6b shows lanes printed with an intended space of 5 µm 
between them. Actual distances were 1.18 ± 0.25 µm (Figure 3.6a) and 4.76 ± 0.24 µm 
(Figure 3.6b), calculated by taking the average intensity profile across the gap between 
lanes and finding the full width at half-maximum value for each. 
Astrocytes were cultured over a two-protein pattern of laminin and aggrecan lanes 
and over appropriate controls (laminin only or aggrecan only patterns). Cells were observed 
to interact with the underlying protein layers and preferential adhesion and alignment to 
the laminin lanes was observed. Figure 3.7 shows the alignment of astrocytes cultured on 
laminin and aggrecan lanes. Alignment along the axis of the laminin lanes was observed in 
samples that contained laminin patterns either with or without aggrecan, while this 
alignment was absent for samples containing only aggrecan lanes (Figure 3.7b). Figures 
3.7c and 3.7d show histograms of astrocyte alignment relative to the axis of the underlying 
protein patterns.
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Figure 3.6: Lane patterns printed with the multiprotein µCP process. Lane patterns were printed with laminin (AlexaFluor 488-labeled) 
and aggrecan (AlexaFluor 592-labeled). (A) Intended lane spacing of 0 µm. (B) Intended lane spacing of 5 µm. 
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Figure 3.7: Alignment of cells on printed multiprotein patterns. (A,B) Fluorescence images 
were produced from the sequential stamping of laminin (green, AlexaFluor 488-labeled) 
and aggrecan (red, AlexaFluor 592-labeled) using two lane stamps with bright field overlay 
of cultured astrocytes. Astrocytes were seen to interact with the underlying laminin pattern 
but not the underlying aggrecan pattern. (C) Histogram showing the alignment of astrocytes 
cultured on laminin and aggrecan lanes relative to underlying pattern (n = 179). (D) 
Histogram showing the alignment of astrocytes cultured on aggrecan lanes relative to 
underlying pattern (n = 97). 
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3.4 Discussion 
When aligning multiple stamps, it is important to eliminate motion in the system to 
ensure the image taken of the first stamp in contact with the surface continually represents 
the distribution of the first transferred protein species. In printing multiple proteins, the 
greatest source of alignment error is introduced in the leveling process. During leveling, 
the microscope turret is rotated between the attached substrate and a separate objective 
lens. This mechanical system has an intrinsic amount of deviation at each of these set 
positions. Any deviation in the position of the turret will cause an offset between the image 
of the first pattern and the actual location of the transferred protein pattern. This will cause 
the second protein pattern to be deposited slightly out of alignment with the first. The 
amount of error introduced in this step is within the tolerance of the designed application 
of the system. It is important to note, however, that for certain stamps, leveling is less of a 
concern. Depending on the distribution of features on the stamp, variations in pressure 
across the stamp can have either profound or little effect on the fidelity of pattern transfer. 
Additionally, the elastic modulus of PDMS can be tailored to reduce the need for stamp 
leveling. For stamp systems in which pressure variations have little effect, the leveling step 
can be skipped and thus reduce error in pattern transfer. 
As illustrated in Figure 3.5, this technique can be used to precisely register multiple 
patterns of proteins. The image in Figure 3.5e shows what the user observes while aligning 
a second stamp with a previously transferred pattern. The first stamp is loaded and brought 
into contact with the substrate. An image of this stamp in contact with the substrate (Figure 
3.5b) is used in conjunction with the live image of a second stamp (Figure 3.5d) to ensure 
the two patterns are in registry before stamping. In this example, the features from the 20 
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% random coverage stamp can be seen through the holes in the live image of the 
complementary stamp (Figure 3.5e). Once the patterns are aligned, the second stamp is 
brought into contact with the surface, thus transferring the second pattern of proteins. This 
demonstrates the precision afforded by this method in the x, y, and rotational degrees of 
freedom. Higher order patterned systems can be easily created with the same degree of 
accuracy. 
The precise control of alignment allows for the transfer of multiple protein patterns 
to the same surface in registry. Figure 3.6 demonstrates the control over spacing between 
printed lane patterns. Both laminin (AlexaFluor 488) and aggrecan (AlexaFluor 592) were 
used as they are two proteins of interest in the study of neuronal guidance in spinal cord 
injury bridging devices. Images of each species were obtained separately using appropriate 
filters that were then combined to form the final image. Precision in alignment is 
demonstrated by the proximity of stripes in the x-direction and the rotational orientation. 
Spacing between lanes was controlled with an accuracy of ~1 µm at two different spacings, 
0 and 5 µm. 
This pattern is fundamentally different from current two-protein patterns in that it 
is continuous over a large area (1 cm2) and the two species were precisely deposited in 
register with one another. Conventional large area, two-protein patterns were previously 
generated by backfilling one of the proteins, which might have resulted in nonspecific 
binding and interactions with previously deposited protein layers.198 Other multiprotein 
patterns have been generated through the stamping of a single substrate in serial; however, 
no known current methodologies have the precision and repeatability demonstrated by this 
method. The current method allows for the presence of nonpatterned space within a 
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multiprotein system, which conventional methods cannot produce. 
Astrocytes cultured over laminin and aggrecan lanes were seen to interact with the 
underlying protein patterns. Cells were observed to preferentially adhere to laminin lanes 
(versus nonstamped and aggrecan lanes), and aligned along the axis of the pattern. This 
was expected, as laminin lanes have been previously shown to induce alignment in cultured 
astrocytes.220 Aggrecan, typically implicated in inhibiting neuronal guidance, was not seen 
to play a significant role in modifying astrocyte behavior versus nonstamped controls. The 
interaction of cells with the underlying protein patterns demonstrates the transfer of an 
active protein species to the surface in a controlled pattern and validates this method as a 
surface-patterning tool. 
 
3.5 Conclusion 
Presented here is the description of a technique developed for the deposition of 
multiple independent protein patterns on the same surface. The integration of live-imaging 
capabilities makes possible the precise alignment of multiple stamps and introduces 
valuable imaging tools in situ. The capabilities of this method to align and print multiple 
protein patterns in precise registration have been demonstrated, as has the bioactivity of 
these transferred patterns. The verification of this technique addresses a previously unmet 
need in the field of µCP. 
 
  
CHAPTER 4 
 
DETECTION OF SYNERGY IN PLATELET PRIMING PATHWAYS USING 
MULTIPLE SURFACE BOUND AGONISTS IN FLOW 
 
4.1 Introduction 
Current platelet function tests fall short in their ability to predict adverse clinical 
outcomes. This is partially due to the complexity of currently available methods and the 
effect that confounding factors like patient hematocrit, sample handling, and anticoagulant 
selection have on results.120,122,126,131 This can also be attributed to the fact that no current 
platelet function assay takes into account the priming effect in platelets. Platelets 
encountering a damaged vessel or a biomaterial interact with a complex milieu of agonist 
molecules, and it has been shown that the majority of platelets that become incident on an 
agonist surface do not end up making stable adhesions.83 It has also been demonstrated that 
a variety of agonist molecules can elicit a priming response from platelets.81,82 Previous 
work has shown that a surface-bound agonist is capable of priming platelets for enhanced 
adhesion downstream (see Chapter 2); however, the effect that multiple priming agonists 
have on a platelet population has not been studied.84,85 This chapter documents the 
integration of a multiagonist priming region into a platelet function assay and posits the 
existence of a synergistic effect between platelet priming pathways.
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4.1.1 Transient Contacts 
When a platelet initially becomes incident on a biomaterial or damaged vessel, it 
first forms an adhesive bond with von Willebrand factor (vWF) that is either adsorbed to 
the material surface or associated with collagen in the vascular extracellular matrix 
(ECM).75 The bond that forms between the GPIb-IX-V complex and vWF is characterized 
by an extremely quick on-off rate, which allows for the capture of rapidly moving platelets 
from circulation.224,225 The shear strengthening nature of this catch bond leads to a stop-
start pattern in their motion across the surface.44,46 Once sequestered from flow, platelets 
translocate along the surface through the rapid association and disassociation of these 
bonds.  
Due to its critical role in initiating contacts between platelets and surfaces, the 
nature of this bond has been investigated thoroughly.226–228 The quick on-off rate of this 
bond not only allows for the capture of platelets from flow, but also for the rapid 
disassociation of platelets from the surface. Indeed, it has been observed that the majority 
of platelets do not make stable adhesions with a surface, but instead return to circulation.83 
This adhesion to, translocation on, and release from an agonist-covered surface likely 
serves to prime a platelet population for enhanced adhesion and activation at a downstream 
location. 
Numerous recent studies have used microfluidic devices to investigate the 
interaction between platelets and artificial surfaces, incorporating agonists such as surface-
bound proteins and shear. 161,179,229 Very few of these studies, however, have taken into 
account the transient nature of platelet-surface contacts.83,230  
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4.1.2 Platelet Priming Pathways 
Implanted biomaterials and sites of vascular damage are characterized by a complex 
mixture of adsorbed and exposed molecules including blood plasma proteins and the 
endothelial ECM. As a platelet rolls across a surface, it is therefore likely that they are 
exposed to a variety of different agonist molecules such as fibrinogen, vWF, or collagen. 
Platelets interact with agonists through many different surface receptors, including 
GPIIb/IIIa, GPVI, integrin α2β1, and the GPIb-IX-V complex, each of which initiates a 
signal transduction pathway within the platelet. The integrated response of a platelet to 
each of these stimuli is what determines the final activation state of a platelet.231  
As with all cells, platelets use common internal signaling pathways which may 
result in synergistic effects that cannot be anticipated through the study of single agonists 
alone. Activation pathways, for example, start with unique surface membrane receptors, 
but use a number of common signal transduction molecules such as phospholipase C (PLC) 
isoforms, protein kinase C (PKC), and calcium ions (Ca+2), and eventually converge to 
activate GPIIb/IIIa, form stable adhesions, and release the contents of granules.232–234 
Figure 4.1 illustrates some common elements in platelet adhesion pathways resulting in the 
activation of GPIIb/IIIa and further amplification events. Given the nature of redundancy 
in the platelet activation pathway, it is not far-fetched to posit similar redundancies built 
into the pathways by which platelets become primed. 235,236 It is therefore of interest to be 
able to stimulate platelets with multiple agonists and measure the priming response elicited. 
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Figure 4.1: Common elements of platelet activation pathways. When an agonist binds to a surface receptor on a platelet, one of a 
variety of isoforms of phospholipase C (PLC) becomes activated. Active PLC releases cytosolic calcium ions from the dense tubular 
system, and also catalyzes the activation of protein kinase C (PKC). Both calcium ions and activated PKC are responsible for the 
conversion of GPIIb/IIIa from a resting to an active state, as well as amplifying other activation pathways, such as the secretion of 
granules and stable adhesion to surface-presented agonists.  
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4.2 Methods 
4.2.1 Flow Cell Creation 
Flow cells were manufactured according to the protocol set out in Section 2.2.1. 
Briefly, polydimethylsiloxane (PDMS Sylgard 184, Dow Corning) was poured into a flow 
cell mold at a ratio of 15:1 (polymer to crosslinker by weight) and allowed to cure. Relief 
for the flow channel features was provided by polymeric tape, which was patterned on a 
laser cutter (VLS3.60, Universal Laser Systems) and attached to the bottom of the mold. 
After release from the mold, fluid vias were bored in the flow cells using a biopsy punch 
(2mm, Robbins Instruments) to allow for inlet and outlet of blood.  
Platelet priming and capture regions were created by microcontact printing (µCP) 
of various platelet agonists. Soft lithographic stamps of varying surface coverage densities 
were created in a process described in Section 2.2.1 and elsewhere.85,184 The surface of 
these stamps was coated with a protein solution and allowed to dry, then inverted onto the 
substrate. Covalent linkages were formed between the agonists and the glass substrate by 
a reactive N-hydroxysuccinimide ester chemistry through the use of commercially 
available Nexterion-H® (Schott) slides.185,186 Stamps were left in contact with the substrate 
for 1 hour to ensure the stable adhesion of protein agonists. Priming regions were stamped 
5 mm from the inlet to allow for the development of laminar flow, and capture regions 
were printed 45 mm downstream of the priming regions. The agonist and surface density 
of the priming regions varied according to experimental conditions; however, capture 
regions consisted of a plain-field (100 % surface coverage) patch of fibrinogen in all 
experiments.  
Devices were assembled by inverting the PDMS flow channels onto the stamped 
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glass substrate. After assembly, nonprinted regions on the substrate as well as the walls of 
the flow channel were passivated by filling the flow channel with a human serum albumin 
solution (1 mg/mL, Sigma Aldrich) for 1 hour prior to perfusion. 
 
4.2.2 Multiagonist Stamping 
Multiprotein µCP was employed to achieve priming regions with multiple agonists. 
The method described in Chapter 3 was used to print agonist patterns of varying surface 
density in registry with their complementary pattern. Experimental conditions were as 
illustrated in Figure 4.2, with the titration of the surface density of one species being offset 
by a complementary surface density of another. For example, mixtures of two agonist 
species, A and B, were created in the ratios of 0A:100B, 30A:70B, 50A:50B, 70A:30B, 
and 100A:0B, as well as unprimed controls. Transfer and alignment of agonist patterns was 
verified using microscopy of fluorophores conjugated to protein agonists through a 
succinimidyl ester chemistry (Alexa Fluor 488, 594). Once the multiagonist stamping 
protocol was established, nonconjugated agonists were used for all priming experiments to 
avoid interference between fluorophores and platelet binding. 
 
4.2.3 Selective Agonist Blocking 
Selective agonist blocking was achieved by incubating the upstream priming region 
with the appropriate antibody solution for 30 min prior to device assembly. Priming regions 
were isolated using a custom removable PDMS micro-well to prevent antibody 
contamination of the rest of the flow channel. Fibrinogen was blocked using goat 
antihuman fibrinogen (Sigma Aldrich). This antibody has been determined to be pure and 
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Figure 4.2: Schematic of multi-agonist experimental conditions. Surface coverage density of agonist A was titrated from 0 % to 100 %. 
The complementary pattern of agonist B was subsequently stamped in registry with the first pattern to create a fully covered field of 
agonist consisting of discrete components of agonist A and agonist B. 
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immunospecific for fibrinogen by the supplier, using immunoelectrophoresis against 
human plasma and fibrinogen. Contaminating antibodies were removed by solid phase 
adsorption with human plasma proteins. Collagen was blocked using rabbit antihuman 
collagen type I (Sigma Aldrich). This antibody has been affinity isolated by the supplier to 
ensure specificity, and was treated to remove any residual lipoproteins. Von Willebrand 
Factor was blocked using sheep antihuman von Willebrand Factor (Haematologic 
Technologies Inc.). The purity of the IgG fraction was verified by the supplier to >95 % 
by SDS-PAGE. The samples were rinsed three times in DDI water following incubation, 
with care taken to not contaminate areas outside of the priming regions. Devices were then 
assembled, passivated with albumin, and used immediately. 
 
4.2.4 Flow Cell Operation 
Flow cell studies were carried out as described in Chapter 2. Whole blood was 
collected from healthy human donors into a 0.105 M sodium citrate solution and was 
anticoagulated with Phe-Pro-Arg-chloromethylketone (PPACK) (Haematologic 
Technologies) to prevent coagulation. A flow rate of 3.6 mL/h was sustained for 5 min in 
each experiment to produce a shear rate of 200 s-1. Devices were then rinsed three times 
with Tyrode’s buffer and fixed in a 4 % paraformaldehyde solution. Attached cells were 
imaged using a differential interference contrast (DIC, Diaphot 300, Nikon) and quantified. 
Adhered platelets were counted in ten randomly selected fields (300 µm x 400 µm) within 
the downstream capture region. Statistical significance was established using unpaired t-
tests. 
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4.3 Results 
4.3.1 Multiagonist Stamping 
Binary-agonist patterns were created at a variety of surface coverage density 
combinations, including 0A:100B, 30A:70B, 50A:50B, 70A:30B, and 100A:0B, where 
species A and B represent fibrinogen, vWF, or collagen (see Figure 4.2). Transfer and 
alignment of the patterns were verified with fluorescent microscopy. Figure 4.3A shows a 
representative image of a stamped agonist combination with surface coverage densities of 
70 % fibrinogen and 30 % collagen. The pattern translational (X, Y) and rotational (Θ) 
alignment error were measured using image processing software (ImageJ) and results were 
averaged over 10 samples.223 Figure 4.3B illustrates the parameters measured in each case. 
The translational and rotational alignment errors were found to be 0.4 ± 0.1 µm and 0.16 ± 
0.03 degrees, respectively. 
 
4.3.2 Agonist Titration 
Agonists were titrated from 0 % to 100 % surface density coverage in pairwise 
combination with complementary patterns of another agonist species. In each case, platelet 
populations that were presented with two agonists displayed a higher priming response 
than those presented with the same total surface coverage density of single agonists. 
Figures 4.4, 4.5, and 4.6 show the number of adhered platelets in the downstream capture 
region in each experimental condition. The fibrinogen-collagen titration showed a marked 
increase in adhesion for conditions that presented multiple agonists versus single agonists, 
the greatest of which was seen to be at a 50A:50B mixture of the two species. The vWF-
collagen titration showed a similar response, with a much greater increase in adhesion 
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Figure 4.3: Quantification of error in the stamping process. A) Example of a transferred 
multi-agonist pattern. Fibrinogen (green, Alexafluor 488) was stamped at a 70 % surface 
density coverage. An inverse pattern stamp was then used to deposit collagen (red, 
Alexafluor 594) at a surface density coverage of 30 %, precisely aligned with the first 
pattern. Scale bar represents 10 µm. B) Parameters used to quantify error in the 
translational (X,Y) and rotational (Θ) alignment of the two stamped agonist patterns. 
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Figure 4.4: Co-presentation of fibrinogen and collagen results in an elevated priming 
response. Fibrinogen and collagen were presented in various combinations of surface 
densities. The combination of multiple agonists is seen to produce a priming response that 
is greater than either of the agonists presented independently. (***p < 0.0005, *p < 0.05) 
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Figure 4.5: Co-presentation of fibrinogen and von Willebrand factor results in an elevated 
priming response. Fibrinogen and von Willebrand factor were presented in various 
combinations of surface densities. The combination of multiple agonists is seen to produce 
a priming response that is greater than either of the agonists presented independently. (***p 
< 0.0005, **p < 0.005) 
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Figure 4.6: Co-presentation of von Willebrand factor and collagen results in an elevated 
priming response. Von Willebrand factor and collagen were presented in various 
combinations of surface densities. The combination of multiple agonists is seen to produce 
a priming response that is greater than either of the agonists presented independently. (***p 
< 0.0005, *p < 0.05) 
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observed at a 50A:50B mixture. In the case of the fibrinogen–vWF combination, the 
maximum response was harder to determine; however, an increased priming response was 
still observed for combined agonists over priming with either fibrinogen or vWF alone. 
 
4.3.3 Selective Agonist Inhibition 
In this experiment, the pairwise agonist titration was repeated, but one agonist 
species in the priming region was selectively blocked with the appropriate polyclonal 
antibody. Figures 4.7, 4.8, and 4.9 show the number of adhered platelets for the blocking 
of single agonist species in each of the agonist combinations. In each case, the blocking of 
one of the agonists served to eliminate the enhanced response seen in the titration 
experiments. A trend, similar to the titration of a single agonist (see Figure 2.3), was 
observed in every combination of agonist pair and antibody. 
 
4.4 Discussion 
Described here is an application of a flow assay that can detect a variable platelet 
priming response as a result of varying agonist species presentation. This assay utilizes the 
concept of platelet priming to determine the activation state of a platelet population using 
a surface capture assay. In the present study, priming regions consisting of variable surface 
density concentrations of agonist pairs were presented to flowing blood. An enhanced 
activation response was observed in experimental conditions that presented the flowing 
blood with multiple agonists when compared to those that presented single agonists. 
Stamping of a single pattern of proteins, then backfilling with a second species is 
the most common way of creating combinations of protein patterns on surfaces; however, 
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Figure 4.7: Selective blocking of fibrinogen in multi-agonist priming conditions. The selective blocking of fibrinogen in a pairwise 
combination results in the recovery of a single-agonist titration response. (***p < 0.0005, **p < 0.005) 
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Figure 4.8: Selective blocking of collagen in multi-agonist priming conditions. The selective blocking of collagen in a pairwise 
combination results in the recovery of a single-agonist titration response. (***p < 0.0005, *p < 0.05) 
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Figure 4.9: Selective blocking of von Willebrand factor in multi-agonist priming conditions. The selective blocking of von Willebrand 
factor in a pairwise combination results in the recovery of a single-agonist titration response. (***p < 0.0005, **p < 0.005) 
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this method was avoided in these experiments due to the affinity that collagen and vWF 
have for each other.57,237 This interaction would make it impossible to control the surface 
densities of each of these species when presented in combination. The creation of 
multiagonist priming regions therefore took advantage of a previously developed technique 
to stamp multiple protein patterns in registry on the same surface (Chapter 3).238 Through 
the use of this technique, multiagonist regions with varying surface coverage densities of 
each species were deposited on a glass substrate. Figure 4.2 shows the combinations of 
agonists used in the experiments, while Figure 4.3A shows an example of a transferred 
pattern combination. Due to the nature of the stamping process, error can be introduced in 
both the translational (x and y) and rotational (Θ) alignments of the second pattern with the 
first (Figure 4.3B). To verify the accuracy of stamp alignment, samples of each agonist 
were tagged with fluorophores, aligned and stamped on a substrate, then imaged with a 
fluorescent microscope. Image processing software was used to assess the total error in 
stamping across 10 test samples. The average stamping error observed was found to be 0.4 
± 0.1 µm of translation and 0.16 ± 0.03 degrees of rotation. 
The consequences of error introduced in the stamping process are twofold. First, 
the total area covered by the stamps will be reduced as gaps are introduced between the 
two complimentary patterns when they overlap. These gaps will end up backfilled with 
albumin during the passivation process and therefore should not present any additional 
priming; however, the maximum priming response may not be achieved in conditions with 
agonist pairs. Second, the ratio of the surface coverage density between the two agonist 
species will be different from what is intended. For example, what was previously a 
70A:30B ratio could become a 60A:30B ratio if a portion of the B agonist pattern was over-
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stamped onto the A agonist pattern. This source of error is unavoidable in this method of 
stamping; however, it can be minimized by careful and precise alignment during the 
stamping process and by always depositing the larger of the two surface coverage densities 
first when generating the upstream priming regions. The translational and rotational errors 
in pattern alignment observed in stamped agonist samples resulted in minimal over-
stamping and gaps in the pattern (Figure 4.3A). The smallest features in these patterns are 
1 µm square, with the vast majority of features being much larger, resulting in pattern 
overlap of very small fractions of the total stamped area. As such, the error in alignment of 
patterns was deemed acceptable for these applications.  
The results of the agonist pair titration experiments suggest that there is an 
enhanced priming response when multiple agonists are presented to a platelet population 
simultaneously compared to single-agonist priming conditions. The pairwise combinations 
had the same theoretical total surface coverage density as the plain field stamps (actual 
coverage would be less if stamping error is accounted for) and yet as seen in Figures 4.4, 
4.5, and 4.6, they demonstrated a significantly higher priming response in each case. These 
results suggest the existence of a synergistic effect between platelet priming pathways.  
Platelet priming depends on the transient interactions of platelets with agonists. In 
the case of these three agonist species, the receptors involved are the GPIb-IX-V complex 
and GPIIb/IIIa for vWF, GPVI and integrin α2β1 for collagen, and GPIIb/IIIa for 
fibrinogen. With the exception of GPIIb/IIIa which has an affinity for both vWF and 
fibrinogen, each of these agonists acts on a separate platelet receptor. Despite differences 
in structure and function, these receptors all share similarities in their signal transduction 
mechanisms. The binding of each of these receptors starts an intracellular signal 
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transduction chain that begins with the activation of one of a variety of PLC isoforms. 
Active isoforms of PLC are responsible for releasing cytosolic calcium ion stores from the 
dense tubular system, and also catalyzing the activation of PKC. Both calcium ions and 
activated PKC serve to amplify other activation pathways such as granule secretion, 
platelet morphology change, and the activation of GPIIb/IIIa (Figure 4.1).235 Recent work 
has explored the crosstalk between platelet adhesion and activation receptors; however, 
much is still left to be discovered.232,233,239,240 
The combination with the most regular pattern of enhanced adhesion was that of 
fibrinogen and collagen (Figure 4.4). As the surface density of the two species was titrated 
from 100 % fibrinogen to 100 % collagen, the number of adhered platelets was seen to 
increase for conditions with two agonists, with a maximum observed at a mixture of 
50F:50C. This suggests that the pathways activated when fibrinogen interacts with the 
GPIIb/IIIa receptor and when collagen interacts with the GPVI and α2β1 receptors act to 
enhance the priming response in a manner that is not merely dose-dependent on each 
species. This implies that there is crosstalk between each of these priming pathways, and 
that the stimulus by multiple agonists serves to enhance the platelet priming response. 
The mixture of vWF and collagen displayed a similar trend as the fibrinogen 
collagen combination, but with a larger enhanced priming response (Figure 4.6). The 
interplay between vWF and collagen in facilitating stable platelet adhesion in vivo has been 
well documented, so it is of little surprise that this combination exhibited the greatest 
enhanced priming response. In this case, each agonist has two main receptors by which to 
interact with platelets, the GPIb-IX-V complex and GPIIb/IIIa for vWF, and GPVI and 
α2β1 for collagen. Through the interaction of each of these agonists with multiple 
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receptors, there is a greater likelihood for a synergy between priming pathways within the 
cell. The redundancy in receptors and priming response is a theme mirrored throughout the 
coagulation response, and this combination of agonists (which best mimics how platelets 
interact with a damaged vessel) is no exception. 
The receptor pair that showed the lowest levels of enhanced priming was that of 
vWF and fibrinogen (Figure 4.5). In each combination, the number of adhered platelets 
was seen to be greater than either vWF or fibrinogen alone, but no trend can be observed 
between each mixed case. This is surprising, as the interplay in binding to these two 
molecules is mainly responsible for the adhesion of platelets to artificial surfaces, and thus 
it is thought that they would exhibit a similar synergy as vWF and collagen which are 
responsible for adhesion in cases of vascular damage. One possible explanation is that the 
GPIIb/IIIa receptor shares an affinity for both of these agonists, thus the priming response 
generated by each of these agonists ends up being shared by the GPIIb/IIIa signaling 
pathway. For example, a platelet that has contacted a vWF patch and interacted via the 
GPIIb/IIIa receptor would trigger this priming pathway, thus subsequent contacts with 
fibrinogen patches would fail to contribute to the priming response. The increased priming 
response observed, however, may be the result of additional VWF interactions with the 
GPIb-IX-V complex. 
These findings were further investigated through the selective blocking of each of 
the agonist species. The initial binary priming experiments were repeated in the presence 
of a polyclonal antibody against one of the two agonists stamped in the priming region. In 
Figures 4.7, 4.8, and 4.9, the results from these studies can be seen, which show that the 
enhanced activation response observed in the case of multiagonist priming was eliminated 
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when platelets were prevented from interacting with one of the species. Instead, results 
indicative of a typical single-agonist titration experiment were observed; i.e., an increased 
downstream adhesion response is generated as a result of a greater priming stimulus. For 
example, when the agonists collagen and fibrinogen were titrated after the priming regions 
had been incubated with anticollagen, a dose-dependent response to the surface 
concentration of fibrinogen was observed, regardless of the concentration of stamped 
collagen. This result mirrors that of a single agonist fibrinogen titration experiment 
performed earlier (see Figure 2.3). Positive controls performed without the presence of an 
antibody confirmed the activity of each blocked species. Since the results of these 
experiments demonstrate a clear dose-dependent response to the nonblocked species, it is 
not anticipated that there is significant cross reactivity between antibodies and the 
nontarget agonist. Further verification could be performed using fluorescently tagged 
antibodies on nontarget antigen surfaces to confirm this assumption. These results 
demonstrate that the interaction of multiple functional agonists with platelet receptors is 
required to generate an enhanced priming response.  
These experiments confirm that the heightened priming response is the result of the 
active interaction of platelets with more than one agonist species. Future work to further 
these findings could use antibodies or small molecule inhibitors to block individual priming 
pathways (as opposed to blocking the agonists) in order to investigate the role that each 
receptor plays in the synergistic effects of multiagonist platelet priming. It would also be 
of interest to see what role antiplatelet agents might play in attenuating the priming 
response generated by multiple agonist pathways. 
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4.5 Conclusion 
In summary, the results presented in this chapter indicate that the stimulation of 
more than one priming pathway leads to an activation response that is more than the sum 
of the parts. Crosstalk between priming pathways likely leads to a synergistic effect which 
creates a higher activation response in a platelet population than can be generated with a 
single agonist alone. The existence of synergy between platelet priming pathways is a novel 
concept that could have broad implications for the fields of platelet activity testing as well 
as antiplatelet therapeutic evaluation. Since platelets in vivo encounter a multitude of 
agonists at surfaces, the ability to investigate the effects of multiple agonists on platelet 
priming and activation in a controlled environment is crucial for the understanding of the 
platelet response to a vascular device or lesion. 
  
CHAPTER 5 
 
SUMMARY AND FUTURE DIRECTIONS 
 
The past 40 years have seen great advancement in the surgical and pharmaceutic 
treatment of cardiovascular diseases. A wide variety of life saving procedures are now 
available to patients with vascular deficiencies, including the implantation of heart valves, 
stents, and shunts. The integration of foreign materials into the body, however, is a process 
that has long been full of challenges. The implantation of biomaterials into the bloodstream 
is particularly challenging, as all known materials—save the native endothelium—
inherently clot blood.7,8 Many approaches have been taken in the device design process to 
reduce the haemostatic response to these materials, including surface coatings engineered 
to reduce protein adhesion, elute antithrombotic and antiplatelet drugs, and be repopulated 
by the native endothelium.68,241–244 The most successful method to date, however, has come 
from the administration of systemic antiplatelet pharmaceutics. Platelets are of particular 
interest due to their central role in binding to surface adsorbed proteins and initiating the 
clotting cascade. To this effect, multiple platelet activation pathways have been identified 
as targets for therapeutics. Drugs such as cyclooxygenase inhibitors, ADP inhibitors, and 
GPIIb/IIIa inhibitors have all met with varying degrees of success in preventing adverse 
outcomes after the surgical introduction of blood contacting devices.95,99,103,245 Not 
everyone in the population responds in the same manner to these treatments, however, with 
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some individuals requiring larger or smaller proportional doses to achieve the desired 
effect.246 Additionally, a certain proportion of the population has been identified as 
nonresponders to common antiplatelet agents such as acetylsalicylic acid (ASA) and 
clopidogrel.17,18,109 This variation in response across the patient population has led to a 
large industry devoted to the assessment of platelet function. Numerous methods have been 
developed and marketed to test the activity of platelets with and without antiplatelet agents 
in both the laboratory and clinical settings.115,120 Despite the wide variety of platelet testing 
methods, there has been little improvement in predicting and preventing adverse clinical 
outcomes such as to postoperative device thrombosis.132,133,141  
 
5.1 Summary of Work 
The goal of the research detailed in this dissertation was to develop new tools with 
which to test platelet activity and the effects of antiplatelet agents. It is our belief that the 
local environment in which platelets interact with thrombogenic surfaces is only one factor 
that determines the activity of a platelet population. To get a more complete picture, the 
history of the platelets as they flow through the vasculature must be taken into account. 
Transient, nonadherent interactions with agonist covered surfaces have the ability to prime 
platelets for enhanced activation and adhesion at locations downstream of the initial 
stimulus. This principle was leveraged in Chapter 2 to create an assay with which to 
measure the activation response of a platelet population primed by an upstream agonist. 
Platelet activity was measured using a surface capture assay, the sensitivity of which was 
enabled by taking advantage of the phenomenon of platelet margination in flowing whole 
blood. The increased propensity for platelets to be at and remain near the wall of the flow 
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chamber due to exclusion by red blood cells made this assay sensitive enough to detect 
incremental changes in the intensity of the priming stimulus. The surface coverage density 
of fibrinogen in the upstream priming region was varied in order to increase or decrease 
the chances that any platelet would encounter an agonist when making transient contacts 
within the priming region. The number of platelets adhered in the downstream region was 
quantified and used as a metric of overall platelet activation. A dose-dependent response 
was observed between the number of adhered platelets and the surface coverage density of 
the priming region, demonstrating the sensitivity of this device to surface-bound antigens. 
This experiment was repeated in the presence of ASA, which was mixed with blood prior 
to perfusion at the recommended concentration for antiplatelet therapy. While a dose-
dependent adhesion response to the upstream priming surface coverage was still observed, 
samples treated with ASA were seen to have significantly fewer platelets adhered than 
nontreated controls. This experiment demonstrated the ability to detect a stimulus 
dependent priming response in the presence of an antiplatelet agent. Finally, in this chapter 
two GPIIb/IIIa inhibitors were tested for their ability to attenuate a platelet priming 
response. Tirofiban and eptifibatide were both added to whole blood prior to perfusion at 
their recommended therapeutic concentration and at 1/10 of that level. Flow cells with 100 
% surface coverage of fibrinogen were used in each case to elicit the maximum priming 
response. With both drugs, a dose-dependent response was observed between the 
concentration of GPIIb/IIIa inhibitor and the number of adhered platelets downstream, 
demonstrating the sensitivity of this assay in detecting the effects of various concentrations 
of antiplatelet agents in blood.  
These experiments provide a proof of concept for the utility of this flow assay for 
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laboratory and clinical applications. The ability to detect the priming response of surface 
bound agonists is of great importance in the development of biomaterials and vascular 
devices. A platform in which researchers can investigate the priming pathways stimulated 
by individual agonists will help tease out the complex platelet priming, adhesion, and 
activation responses that current devices cannot. Additionally, the proof of a priming 
response to upstream agonists can help in dictating device design criteria, which should 
take into account the proximity of potential platelet priming sites such as high-shear regions 
or anastomotic locations. The clinical utility of this assay can be envisioned from the results 
of the antiplatelet studies. The ability to detect the efficacy of an antiplatelet agent in 
response to a variable stimulus, and the ability to detect the dose-dependent response from 
the administration of an antiplatelet agent, demonstrate the potential for this device in 
monitoring antiplatelet therapies. Using this assay, patients could be tested for their 
individual response to a prescribed therapeutic regimen, and nonresponders to individual 
therapeutics could be identified. 
One possible concern with the methodology utilized in this assay arises from the 
use of sodium citrate to reduce the plasma calcium ion concentration in blood samples. 
Blood is drawn into 0.109 M monosodium citrate, which serves to chelate free calcium 
ions. Many coagulation factors require the presence of calcium in order to function 
properly, including the activation of factor X, the conversion of prothrombin to thrombin, 
and the binding of factors Xa and IXa to the surface of platelets. Through the addition of 
sodium citrate, coagulation of the blood samples can thus be avoided during blood draw, 
transport, and handling prior to the introduction of PPACK, a potent thrombin inhibitor.  
The assay described here relies on the detection of an active platelet population 
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through the presence of the active form of GPIIb/IIIa on the surface of platelets. The 
association of GPIIb and GPIIIa is indeed calcium dependent; however, this process relies 
on the intracellular ion concentration and is largely independent of the plasma ion 
concentration.247 An increase in cytoplasmic calcium concentration is caused by the 
association of one or more agonists with receptors on the platelet surface which cause a 
release of ions from the dense tubule system. These ions function to activate GPIIb/IIIa as 
well as regulate granule release reactions and facilitate stable adhesion and spreading 
through cytosolic reactions, which are unaffected by the plasma citrate concentrations.  
Additionally, the introduction of sodium citrate to blood does not result in the 
elimination of calcium ions altogether. The dissociation of calcium ions from citrate salts 
have a pKa of 3.1, resulting in a reduced but measurable concentration of calcium in blood 
with a normal pH of 7.35.248 The mean extracellular calcium ion concentration in blood 
treated with 3.8% sodium citrate was measured by Callan et al. and found to be 0.22 ± 0.02 
mmol/L.249 If, in the future, it is desired to study particular aspects of the coagulation 
cascade that require the presence of extracellular calcium using this assay, it is possible to 
add back free calcium ions to the blood prior to perfusion, or to eliminate the use of sodium 
citrate altogether by drawing blood directly into PPACK.   
Another possible concern with this approach stems from experiments done by 
Horbett and Slack, which highlight the differences in adsorption characteristics of 
fibrinogen to surfaces under various surface and solution conditions.250,251 In the current 
studies, the surface is constant in all cases (Nexterion slide H), the surface is patterned via 
microcontact printing (not solution adsorption), and the concentration of fibrinogen is kept 
constant across samples, irrespective of surface coverage density. The resulting 
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conformations of fibrinogen deposited on the priming and capture regions of all assays 
should therefore be consistent with each other, and are not subject to differences in 
adsorption kinetics or packing densities. 
To further investigate the utility of this device, it was important to develop a method 
by which to pattern multiple proteins on the same surface so as to measure the response of 
a platelet population to multiple surface bound agonists. Traditional methods of 
multiprotein surface patterning such as dip pen nanolithography, inkjet printing, and 
microcontact printing all suffer from the lack of ability to pattern multiple patterns of 
proteins in precise registry across a large scale (~1 cm2).198 Chapter 3 details the 
development of a method to overcome these limitations. Taking advantage of advances in 
microcontact printing that enable micron-scale features, combined with the precise 
registration and optics of a modern light microscope, a new method by which to stamp 
multiple aligned patterns was created. In this process, an inverted light microscope was 
modified to hold both a micropatterned PDMS stamp and a glass substrate. The z-motion 
of the microscope stage provided the ability to bring the stamp in and out of contact with 
the substrate, while optics allowed for the visualization of this process in real time. By 
taking an image while a stamp was in contact with a substrate, the precise locations of 
features transferred to the substrate from the stamp were recorded. This image was then 
overlaid on the live image during subsequent stamping steps, which enabled the alignment 
of additional patterns with the first. In this way, multiple aligned patterns of proteins with 
micron scale features were created over large areas. Past work has shown that surfaces 
microcontact printed with proteins can become contaminated by oils or impurities from the 
PDMS stamp. This source of contamination was reduced in the experiments described in 
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the previous chapters using a couple of methods. The degree of contamination transferred 
to a surface has been shown to be a function of curing time of the polymer, with longer 
cure times resulting in lower amounts of contamination.252 By allowing the PDMS stamps 
and microchannels to cure at room temperature as opposed to curing in an oven, a long 
cure time ( > 24 hours) was achieved, thus reducing levels of contamination. Additionally, 
all new stamps and microchannels were subject to a soak in xylene, which has been shown 
to be effective in reversibly swelling the polymer and extracting unbound monomers and 
contaminants.253 These methods will help in reducing the leeching of oils and monomers 
from the silicone; however, the elimination of such contamination should be verified using 
methods such as TOF-SIMS on the final stamped patterns. The development of this method 
was essential for the recreation of more complex priming environments with which to 
investigate multiple priming pathways in platelets.  
When interacting with vascular lesions or implanted biomaterials, platelets 
encounter a wide variety of surface-presented agonists. It is logical to presume, with the 
number of redundancies built in to the platelet activation process, that multiple surface 
bound agonists could share responsibility for the priming effects observed in platelets. It 
was therefore of interest to investigate the ability of multiple agonists to prime platelets in 
flowing blood and observe what, if any, synergistic response platelets might have when 
primed by multiple pathways. Chapter 4 details experiments in which two agonists in 
varying surface coverage ratios were used to prime platelets in flowing whole blood. Using 
the technique developed in Chapter 3, flow cells were created that had two agonists in the 
priming region.  Complementary stamp patterns were used to titrate the amount of each 
agonist species present, yet keep the total (theoretical) surface coverage density of the 
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priming region at 100 %. Blood was then perfused through the device as before, and 
adhered platelets in a downstream capture region were counted as a metric of activation. A 
synergistic priming effect was observed between pairs of platelet agonists, which resulted 
in enhanced adhesion in samples that were presented with multiple agonists as opposed to 
each agonist individually. The observed adhesion response was greater than would be 
anticipated from combinations of each agonist alone, that is to say, the total adhesion was 
observed to be greater than the sum of the parts. This phenomenon was verified by 
repeating each agonist pair titration in the presence of a polyclonal antibody against each 
species. The presence of a polyclonal antibody against one of the agonist species served to 
block platelet interaction with that species and prevent its contribution to the priming 
response. The result in each case was the recovery of a trend that mirrored that of a single 
agonist titration such as the one observed in Chapter 2.  
These experiments demonstrate the sensitivity of this method in detecting the 
combinatorial response to multiple platelet agonists. The ability of platelets to become 
primed by transient interactions with surface-bound agonists has only recently been 
discovered, and the synergistic effects observed from stimulation of multiple priming 
pathways is a novel concept. This discovery could have implications in the design of 
biodevices in which the controlled surface presentation of specific molecules is of 
particular interest. Additionally, the presentation of multiple agonists provides a platform 
with which to test the effect of antiplatelet agents on the attenuation of individual priming 
pathways.  
Taken collectively, these experiments contribute to the field of platelet activation 
study by providing a controlled environment in which to investigate the priming response 
98 
 
of platelets after transient exposure to a surface bound agonist. This upstream-priming 
downstream-activation response can be modified to investigate a wide variety of conditions 
by varying the strength and composition of the platelet agonist, alone or in the presence of 
antiplatelet agents. This ability is crucial for the future testing of biomaterials, as the 
priming effect of surface bound agonists has only recently been realized. The ability to 
detect the effects of common antiplatelet drugs on a platelet population also suggests a 
clinical application for these methods in the monitoring of antiplatelet therapies in the 
perioperative period of cardiovascular procedures. Finally, the development of novel 
antiplatelet therapies could benefit from the ability to rapidly screen their efficacy in 
attenuating activation in response to common agonists compared to current standards of 
care. 
 
5.2 Future Directions 
5.2.1 Device Design and Production 
Despite the positive results seen from the assay generated for these studies, 
significant improvements could be made to improve on the design and production of this 
device. Due to the small number of flow cells needed for these studies, the methods by 
which fluidic channels were produced remained rudimentary. For example, each flow cell 
was cast, released, trimmed to size, bored for fluid vias, and assembled by hand. If the 
production of these devices were to be scaled up, they would benefit greatly from 
technologies aimed at the mass production, such as large-scale laser cutters, injection 
molds, or roll to roll processes.254 Currently, capillary forces are responsible for holding 
the PDMS flow cell onto the glass substrate, which has proven to prevent leaks over the 
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duration of these experiments. Commercial devices, however, would need to be shelf-
stable for long periods of time, so more advanced bonding methods would need to be 
employed such as the plasma treatment of contacting PDMS and glass surfaces or chemical 
adhesive methods. Additionally, other materials besides PDMS, such as poly(methyl 
methacrylate), polystyrene, or polycarbonate, might be considered in the production of 
flow channels for their ease in patterning by commercial laser equipment, rigidity for 
handling concerns, and ability to be bound to substrates.255,256  
The flow channel design in these studies was kept macroscale, with dimensions of 
1 mm x 70 mm x 0.1mm, both for ease in device manufacturing and consistency across all 
experiments. Future iterations of a similar upstream-priming downstream-adhesion assay 
could benefit greatly from a reduction in dimension, which would serve to decrease sample 
size and allow for the investigation of more conditions on a single device. The 
incorporation of an on-device pumping system or gravity fed flow could also reduce the 
countertop footprint of the assay and eliminate the need for an external syringe pump, 
though precise control of the shear rate would have to be investigated. Through the use of 
a platelet-specific antibody conjugated with a fluorescent tag, such as anti-CD42a or anti-
CD61 (either through premixture or introduction in-device) a mechanism could be 
designed that images and detects platelets similar to an automated plate reader. Such a 
system would greatly reduce the burden to end-users, as the current method requires 
imaging and counting of platelets manually. 
The surface patterning method developed for multiprotein printing could also be 
improved from methods used in currently available technologies. Presently, each stamp is 
leveled and aligned with previous patterns by hand, a tedious and time-consuming process. 
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Commercial photomask aligning tools have long since solved this problem through 
automated leveling and alignment techniques with a much higher degree of precision than 
necessary for these applications. Adaption of these technologies could prove useful for the 
future of large-scale multiprotein patterning and would serve to assist in the upscale of 
production of these devices. 
 
5.2.2 Assay Applications 
The applications of the assay demonstrated here only scratch the surface of its 
potential utility. In the current iteration of the device, there remains opportunity for the 
investigation of other platelet priming pathways. Three common platelet adhesion 
molecules were investigated in these studies; however, recent work has identified a wide 
variety of other molecules that act to prime platelets, such as soluble proteins, cytokines, 
hormones, and prostaglandins, which could provide interesting targets for future studies.81 
The incorporation of molecules such as these into this assay, either through surface 
immobilization or introduction during flow, would give insight into the priming of platelets 
by nonadhesion pathways. Experiments could be carried out as described in Chapter 2, 
with novel agonists stamped in the priming region, or introduced during flow using yet to 
be developed microfluidic devices. The number of adhered platelets to the capture region 
could then be assessed, and it is expected that numbers would vary based on the dose of 
the agonist presented to flowing platelets and the ability of that agonists to produce a 
priming response in platelets. Shear forces serve as another pathway by which platelets are 
activated, and could also be easily incorporated into the current design through the 
introduction of a stenotic priming region.170,181 The degree of stenosis and length of the 
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stenotic region, coupled with the volumetric flow rate through the device, could be used to 
tailor the degree of shear priming stimulus. It is expected that elevated shear forces in an 
upstream position would serve to prime platelets for enhanced adhesion downstream in a 
dose-dependent fashion, with both upper and lower limits on this effect.  
If the substrate of the device is switched out, the principle of upstream-priming and 
downstream-adhesion can also be used to test for priming by other agonist surfaces. By 
linking two devices in serial, one with a biomaterial as a substrate and another with a 
traditional surface capture assay on glass, the response of a platelet population to plasma 
proteins adsorbed to a specific material could be investigated. The use of whole blood 
would enable a protein adsorption response similar to that of an implanted material, and 
platelets would be allowed to interact with a system mimetic of an implanted biodevice. It 
is expected that the platelet priming response would depend on the identity and 
concentration of agonist species adsorbed to the biomaterial surface, which would be a 
function of the surface properties of the biomaterial itself. This would greatly assist in the 
development of novel materials and surface coatings for implanted vascular devices. 
Similarly, vascular lesions could be modeled by growing endothelial cells to confluence 
on a substrate and then introducing a physical scratch wound to the cell layer.257 This 
scratch, when presented to flowing blood similar to assays described previously, could act 
as a priming region for platelets, and would present surface-bound agonists mimetic to 
those present in a vascular injury. It is expected that such a mimetic scratch would prime 
platelets for enhanced adhesion downstream due to the presence of exposed ECM. Finally, 
when surfaces are recolonized by an endothelial cell population (by design or not), these 
cells are typically characterized by an inflamed phenotype.258 The use of tumor necrosis 
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factor (TNFα) to activate a confluent layer of endothelial cells could be useful as a model 
by which to characterize the platelet priming response to this environment.259 Two flow 
chambers hooked in serial could be used to investigate this phenomenon, with the first 
chamber used to expose platelets to inflamed endothelial cells, and the second chamber 
used as a capture assay. It is expected that inflamed endothelial cells will prime platelets 
for enhanced adhesion downstream relative to native or passive endothelial cells. Work 
into the development of an endothelial activation flow cell model is currently ongoing.   
The antiplatelet agent studies performed demonstrated the ability to detect the 
effects of two common antiplatelet pathways, yet a third common family, ADP inhibitors, 
remain uninvestigated. Due to it being a prodrug, cangrelor was excluded from current 
studies to avoid the need to recruit a patient donor population, especially with a 
developmental device. Since it is so widely used, however, it remains a prime target for 
investigation of its efficacy in attenuating platelet activation to surface bound agonists, as 
a significant proportion of the population demonstrates resistance to its effects. To perform 
this experiment, it would be necessary to recruit a population currently taking these 
prodrugs and repeat experiments as described in Chapter 2. It is expected that these drugs 
will attenuate the platelet priming response in a manner similar to GPIIb/IIIa inhibitors, 
due to their function of blocking internal activation pathways. There are a variety of other 
families of antiplatelet agents, including phosphodiesterase inhibitors, protease-activated 
receptor-1 inhibitors, adenosine reuptake inhibitors, and thromboxane inhibitors, each of 
which would be of interest for future studies.260 This assay, with further development, 
could also prove useful as an efficient and cost-effective way to compare developmental 
drugs against currently recommended treatments in order to identify promising candidates.  
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Finally, the multi-agonist studies indicate that platelet priming pathways display a 
synergistic response that leads to enhanced activation and adhesion downstream of a binary 
agonist stimulus. These results suggest that there is a combinatorial priming response in 
platelets that interact with two or more agonists, likely due to crosstalk among intracellular 
priming pathways.232,234,240 In these studies, only three common adhesion molecules were 
used, with each combination displaying similar trends, but varying degrees of synergy. The 
difference in the synergistic response observed for each of these pairs is thought to arise 
from the number and type of receptors that platelets have for each of these agonists; 
however, more studies are needed to confirm this hypothesis. The blocking of individual 
receptors on the surface of platelets would be a logical next step in teasing out the 
intricacies of this synergistic response. This experiment could be performed by repeating 
the agonist titration experiments described in Chapter 4, but in the presence of antigens for 
individual surface receptors for each agonist. It is expected that a synergistic priming 
response would still be observed, but this response would be diminished based on each 
receptor’s individual contribution to the synergy. It would also be a logical extension of 
previous experiments to see how well antiplatelet agents do in attenuating the priming of 
platelet populations stimulated by multiple agonists. Recent theories have emerged 
postulating that individual resistance to antiplatelet agents is not due to the inefficacy of 
the drug, but that platelets are being activated by a pathway outside the target of the 
antiplatelet agent.260 For example, if a patient was treated with ASA (which serves to 
inhibit cyclooxygenase) but had a thrombin-mediated activation stimulus, there might still 
exist a significant activated platelet population as these two pathways are independent. 
That individual might then be found to have an active platelet population and be classified 
104 
 
as a nonresponder to ASA treatment. Through the presentation of multiple agonists to 
platelets in flowing whole blood, the concept of antiplatelet resistance can be further 
explored through the isolation of individual activation pathways. 
  
  
APPENDIX 
 
STABILITY OF THE ALBUMIN PASSIVATION LAYER 
 
A possible cause of concern with the current assay design is the stability of the 
adsorbed albumin layer. If the reactive NHS esters on the glass substrates are not 
sufficiently backfilled with albumin, blood soluble proteins could adsorb to the surface and 
create additional agonist regions which might serve to enhance the priming response of the 
platelet population. The use of albumin to passivate platelet flow cell surfaces has been 
previously established and validated in our lab.85,261 Methods to elute proteins from 
surfaces using surfactants are also well established and were used to further probe the 
stability of adsorbed albumin.262,263 
A Nexterion-H® (Schott) slide was printed with a 50 % surface coverage pattern of 
fibrinogen (unlabeled, 1 mg/mL in PBS, Sigma Aldrich) and then backfilled with 
fluorescently labeled albumin (1 mg/mL, Sigma Aldrich) (Alexa Fluor® 488, Sigma 
Aldrich). Figure A.1 shows the presence of adsorbed albumin both in between stamped 
islands of fibrinogen and in the rest of the flow channel. Figure A.1A shows the pattern 
immediately postadsorption, while Figure A.1B shows a region at the border of the stamped 
pattern on the same sample after an 18-hour incubation in 1 % surfactant (Alconox®) 
solution, followed by a 30-min sonication in a fresh surfactant solution.  
The labeled albumin was seen to adhere to the NHS groups left unreacted after the
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Figure A.1: Stability of the albumin passivation layer. A Nexterion-H® slide was stamped 
with a 50 % coverage pattern of fibrinogen (unlabeled) and backfilled with albumin (Alexa 
Fluor® 488). (A) Albumin was observed to interact only with NHS ester groups not 
previously occupied with stamped fibrinogen. (B) The stability of the pattern was verified 
after an 18-hour incubation and 30-min sonication in a surfactant solution both in the 
stamped region (left) and flow channel (right). Scale bar represents 10 µm. 
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printing of fibrinogen, both in the priming region as well as in the rest of the flow cell. 
Albumin did not interact with the previously deposited fibrinogen as indicated by the 
visible pattern in the printed region. The stability of the adhered protein despite an 
aggressive treatment with surfactant solution lends credibility to the idea that it is 
covalently attached. 
These data show that albumin can be solution adsorbed to the surface of the flow 
cell and that it does not interfere with previously bound printed proteins. Additionally, the 
adsorbed protein layer is stable for long periods of time in environments designed to 
remove nonbound proteins; therefore, the state of the surface is not expected to appreciably 
change over the short time course of the flow assay experiments (5 min).  
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